Patent Application
20230340003
The present invention relates to processes for preparing soluble salts of inositol phosphates, the compounds obtained thereby, compositions containing the compounds, and methods of using the compounds and compositions for treating ectopic calcifications in human health.
Inositol hexaphosphate (IP6, phytic acid, phytate) is a potent inhibitor of the crystallization of calcium salts (Grases F, et al., Anticancer Res. 1999; 19:3717-3722). As it is a molecule with six phosphate groups, it shows a high affinity for divalent and trivalent metallic ions such as calcium. This property allows IP6 preventing the development of pathological calcifications, such as renal lithiasis (Conte A, et al., Arch. Esp. Urol. 1999; 52:305-310) or cardiovascular calcifications (Grases F, et al., Front. Biosci. 2006; 11:136-42), among others. This property also allows it to chelate calcium ions in environments such as the intestinal tract, where it can prevent or treat Clostridium difficile infections (Kreimeyer I, et al., Naunyn Schmiedebergs Arch Pharmacol. 2011; 383(3):253-262.
IP6 is a molecule abundant in vegetable seeds and legumes. Between 1.5% and 6.4% of the dry weight of grains consists of IP6 (Reddy N, Sathe S, Eds., Food phytates (CRC, Boca Raton, FL, USA, 2002); Schlemmer U, et al., Mol. Nutr. Food Res. 2009; 53:S330-S375)). It may also be found in all organs and tissues of animals in ionized form (Grases F, et al., J. Nutr. Chem. 2001; 12:595-601). Most of the IP6 currently used is of vegetable origin.
In the plant and seed tissues, IP6 is naturally present as a mixture of K, Mg, Ca, Mn, Zn and Fe salts of IP6 (Frossard E, et al., J. Sci. Food Agric. 2000; 80:861-887). The most abundant IP6 salt is its Ca-Mg salt also known as phytin (Bhatty R, et al., Can. Inst. Food Sci. Tech. J. 1989; 22:137-142; Yoshida K, et al., Plant Physiol. 1999; 119:65-72). However, phytin is insoluble in water and is thus inadequate for preparing aqueous solutions for intravenous administration.
The IP6 commercially available is obtained mainly from raw materials such as rice bran or corn steep liquor. These materials are treated with organic or inorganic acids to extract phytin, which is then precipitated and separated from the extract, usually by filtration, to remove any unwanted proteins and carbohydrates. Afterwards, phytin is hydrolyzed under pressure to recover IP6. Various methods based on the use of ionic exchange columns for extracting IP6 and its salts have been described in the art (Harland B, et al., Cereal Chem. 1977; 54:827-32). See also, US2718523 describing the preparation of phytic acid and soluble salts thereof by cation exchange; US2750400 describing the preparation of phytic acid from calcium magnesium phytates using cation exchange; and US4668813 describing the preparation of phytin using anion exchange followed by alkali elution. In addition, CN102964381 describes the purification of IP6 by an ethanol crystallization process; and WO1992016534 describes a process for the direct purification of phytate using a solid-phase free base polymer having tertiary amine functions.
IP6 and its salts have many therapeutic applications. For instance, calcium phytate is used as calcium enrichment, while sodium phytate is used for the prevention of the relapse of calculosis, and potassium phytate is used for the treatment of hypercalcemia. More recently, the hexasodium salt of IP6 (Na6IP6) has been employed for reducing or preventing pathological calcification (
Na6IP6 has also been used in formulations indicated for reducing cardiovascular events related to cardiovascular calcification (CVC) in patients with end stage renal disease (ESRD) undergoing hemodialysis (HD). See Clinical Trail NCT02966028 (Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)) at https://clinicaltrials.gov/, December 2020.
Thus, there is present need in the art for soluble salts of inositol phosphate (e.g., Na6IP6) having a high degree of purity and for processes for its preparation thereof which are industrially scalable, reproducible, and safe.
The present invention provides a process for purifying (i.e., recrystallizing) an inositol phosphate (IP) salt, the process comprising the steps of (i) dissolving the IP salt in water to obtain an IP solution, (ii) converting the IP solution to an IP suspension, (iii) washing the IP suspension with an alcohol solution to obtain a solid, and (iv) drying the solid to obtain the purified (i.e., recrystallized) IP salt.
In some aspects, the IP salt and water of step (i) are mixed in a 1:2 weight ratio. In some aspects, the IP solution of step (i) is heated. In some aspects, the IP solution is heated at about 45° C. to about 50° C. In some aspects, the IP solution is heated for about 4 hours or less. In some aspects, the IP solution is heated for about 2 hours or less. In some aspects, the IP solution is filtered. In some aspects, the IP solution is seeded with crystals of the IP salt previously recrystallized. In some aspects, the IP solution is seeded with crystals of the IP salt previously recrystallized representing about 0.4% (w/w) or less of the IP salt of step (i). In some aspects, the IP solution is seeded with crystals of the IP salt previously recrystallized representing about 0.2% (w/w) or less of the IP salt of step (i). In some aspects, the IP solution is seeded with crystals of the IP salt previously recrystallized representing about 0.1% (w/w) or less of the IP salt of step (i).
In some aspects, the IP solution is stirred. In some aspects, the alcohol solution in step (iii) comprises, consists or consists essentially of a C1-C4 alcohol. In some aspects, the C1-C4 alcohol is ethanol. In some aspects, the drying of the solid of step (iv) is conducted at about 50° C. or less.
The present invention also provides a process for preparing a soluble salt of an inositol phosphate (IP), the process comprising the steps of (a) dissolving an IP salt in water to obtain an IP solution, (b) contacting the IP solution with an ion exchange medium, (c) concentrating the ion exchanged IP solution from step (b) to obtain an IP syrup, and (d) separating the soluble IP salt from the IP syrup in the presence of an alkoxide.
In some aspects, the present invention provides a process for preparing a purified soluble salt of an inositol phosphate (IP), the process comprising the steps of (a) dissolving a purified (i.e., recrystallized) IP salt in water to obtain an IP solution, (b) contacting the IP solution with an ion exchange medium, (c) concentrating the ion exchanged IP solution from step (b) to obtain an IP syrup, and (d) separating the purified soluble IP salt from the IP syrup in the presence of an alkoxide.
In some further aspects, the present invention also provides a process for preparing an unpurified soluble salt of an inositol phosphate (IP), the process comprising the steps of (a) dissolving an unpurified IP salt in water to obtain an IP solution, (b) contacting the IP solution with an ion exchange medium, (c) concentrating the ion exchanged IP solution from step (b) to obtain an IP syrup, and (d) separating the unpurified soluble IP salt from the IP syrup in the presence of an alkoxide.
In some aspects, the present invention provides a process for preparing a purified soluble salt of an inositol phosphate (IP), the process comprising the steps of (i) dissolving an IP salt in water to obtain a first IP solution, (ii) converting the first IP solution to an IP suspension, (iii) washing the IP suspension with an alcohol solution to obtain an IP solid, (iv) dissolving the IP solid in water to obtain a second IP solution, (v) contacting the second IP solution with an ion exchange medium, (vi) concentrating the ion exchanged IP solution from step (v) to obtain an IP syrup, and (vii) separating the purified soluble IP salt from the IP syrup in the presence of an alkoxide. See General Scheme 1. In some aspects, the purified soluble IP salt of step (vii) is dried. In some further aspects, the purified soluble IP salt of step (vii) is spray-dried.
#
Wherein A is a monovalent cation such as an alkali cation (e.g., Na+, K+), ammonium (i.e., NH4+) or a combination thereof. In some aspects, the cation of the end product B may be the same (i.e., A = B) or different from the cation of the starting material (e.g., a potassium IP salt is used as starting material and is treated with a sodium alkoxide to yield a sodium end product, See Example 13).
In some aspects, the ion exchange medium is an ion exchange chromatography, batch process or pH adjustment system. In some aspects, step (c) is conducted by distilling the IP solution at about 55° C. or less.
In some aspects, the alkoxide is a C1-C4 alkoxide. In some aspects, the C1-C4 alkoxide is CH3NaO, CH3CH2NaO, CH3KO or CH3CH2KO. In some aspects, step (d) is conducted between about pH 4.0 and about pH 5.5. In some aspects, the process further comprises (e) spray drying the soluble IP salt of step (d). In some aspects, the soluble IP salt of step (a) has been previously recrystallized according to a recrystallization process disclosed herein. In some aspects, the soluble IP salt of step (e) is further recrystallized according to a recrystallization process disclosed herein.
In some aspects of the processes disclosed herein, the IP contains between 1 and 8 phosphate groups. In some aspects, the IP contains between 1 and 6 phosphate groups. In some aspects, the IP is inositol hexaphosphate. In some aspects, the inositol hexaphosphate is myo-inositol hexaphosphate. In some aspects, the IP salt contains at least one monovalent cation. In some aspects, the monovalent cation is (i) a Group 1 alkali metal element cation, (ii) ammonium or (iii) a combination thereof. In some aspects, the Group 1 alkali metal element is sodium, potassium or a combination thereof.
The present invention also provides a purified soluble IP salt obtained according to any of the processes disclosed herein. In some aspects, the purified soluble IP salt is a monovalent cationic salt of inositol monophosphate (IP1), inositol biphosphate (IP2), inositol triphosphate (IP3), inositol tetrakisphosphate (IP4), inositol pentaphosphate (IP5), inositol hexaphosphate (IP6) or a combination thereof. In some aspects, the purified soluble IP salt is at least 70% (w/w), at least 75% (w/w), at least 80% (w/w), at least 85% (w/w), at least 90% (w/w) or at least 95% (w/w) pure.
In some aspects, the purified soluble IP salt is a monovalent cationic salt of IP6 (e.g., Na5IP6, Na6IP6, K4IP6, K6IP6, (NH4)6IP6). In some aspects, the purified soluble IP salt is Na6IP6. Accordingly, the present invention also provides an IP6 salt, for example hexasodium salt, that is at least 70% (w/w) pure comprising (i) DL-Inositol 1,2,3,4,6-pentaphosphate ≤ 2.0% (w/w), (ii) DL-Inositol 1,2,3,5,6-pentaphosphate ≤ 4.0% (w/w), (iii) DL-Inositol 1,2,4,5,6-pentaphosphate ≤ 5.0% (w/w), and, (iv) DL-Inositol 1,3,4,5,6-pentaphosphate ≤ 3.0% (w/w). Also provided is a Na6IP6 salt that is at least 80% (w/w) pure comprising (i) DL-Inositol 1,2,3,4,6-pentaphosphate ≤ 1.4% (w/w), (ii) DL-Inositol 1,2,3,5,6-pentaphosphate ≤ 2.1% (w/w), (iii) DL-Inositol 1,2,4,5,6-pentaphosphate ≤ 2.6% (w/w), and (iv) DL-Inositol 1,3,4,5,6-pentaphosphate < 0.52% (w/w).
The present invention also provides pharmaceutical compositions comprising IP salts prepared according to the methods disclosed herein, e.g., the Na6IP6 salt, and combinations thereof. In some aspects, the pharmaceutical composition is injectable. In some aspects, the pharmaceutical composition is administered parenterally. In some aspects, the parenteral administration is intravenous. In some aspects, the intravenous administration is via intravenous infusion. In some aspects, the pharmaceutical compositions comprising the IP salts prepared according to the methods disclosed herein are stable at room temperature (i.e., 25° C., 60% RH) for at least 6 months.
The present invention also provides combination treatments comprising a compound prepared according to the process of any one of claims, a purified soluble IP salt prepared according to the methods disclosed herein (e.g., Na6IP6, K6IP6, (NH4)6IP6)) or a pharmaceutical composition disclosed herein in combination with one of more (e.g., a second or a third) therapeutic agent and/or treatment disclosed in Table 1.
Also provided is a kit or product of manufacture comprising (i) a compound prepared according to the process of any one of claims, a purified soluble IP salt prepared according to the methods disclosed herein (e.g., Na6IP6, Na5IP6, K4IP6, K6IP6, (NH4)6IP6), a pharmaceutical composition disclosed herein or a combination treatment disclosed herein, and (ii) instructions for administration.
The present invention also provides methods for treating or preventing ectopic calcification or its consequences in a subject in need thereof which comprises administering a compound prepared according to the process of any one of claims, a soluble IP salt prepared according to the methods disclosed herein (e.g., Na6IP6), a pharmaceutical composition disclosed herein, a combination treatment disclosed herein or a kit disclosed herein to the subject. Alternatively, the present invention provides a compound prepared according to the process of any one of claims, a soluble IP salt prepared according to the methods disclosed herein (e.g., Na6IP6), a pharmaceutical composition disclosed herein, a combination treatment disclosed herein or a kit disclosed for use in the treatment or prevention of ectopic calcification or its consequences in a subject in need thereof. Alternatively, the present invention provides the use of a compound prepared according to the process of any one of claims, a soluble IP salt prepared according to the methods disclosed herein (e.g., Na6IP6), a pharmaceutical composition disclosed herein, a combination treatment disclosed herein or a kit disclosed herein in the preparation of a medicament for treating or preventing ectopic calcification or its consequences in a subject in need thereof. In some aspects, the subject is undergoing hemodialysis. In some aspects, the subject has end-stage renal disease.
The present invention relates to processes for preparing soluble salts of inositol phosphate characterized by a low level of impurities. In some aspects, the inositol phosphate salt contains at least one monovalent cation. In some aspects, the monovalent cation is (i) a Group 1 alkali metal element cation, (ii) ammonium or (iii) a combination thereof. In some aspects, the Group 1 alkali metal element is sodium, potassium or a combination thereof. In some further aspects, the preparation of several soluble salts of inositol hexaphosphate (e.g., Na6IP6, Na5IP6, K4IP6, K6IP6, (NH4)6IP6)) are described. In some aspects, the invention provides processes for the preparation of the hexasodium salt of inositol hexaphosphate (Na6IP6) from its dodecasodium salt (Na12IP6), as well as processes for the preparation of the Na12IP6 intermediate (e.g., via recrystallization). The Na6IP6 compound can be used as drug substance in the SNF472 product. This product has undergone phase II clinical trials (See e.g., clinical trial NCT02790073) and is currently in phase III clinical trials.
The present invention also provides compositions, e.g., pharmaceutical compositions, comprising phytate salts (e.g., Na6IP6, Na5IP6, K4IP6, K6IP6, (NH4)6IP6)) prepared according to the methods of the present invention. Also provided are formulations, articles of manufacture, and kits comprising phytate salts (e.g., Na6IP6, Na5IP6, K4IP6, K6IP6, (NH4)6IP6)) prepared according to the methods of the present invention. Also provided are methods of treatment comprising the administration of phytate salts (e.g., Na6IP6, Na5IP6, K4IP6, K6IP6, (NH4)6IP6)) prepared according to the methods of the present invention to a patient in need thereof, e.g., a subject suffering from a disease or condition disclosed herein such as calciphylaxis or cardiovascular calcification.
The invention also provides dosage forms comprising an amount of phytate salts (e.g., Na6IP6, Na5IP6, K4IP6, K6IP6, (NH4)6IP6)) prepared according to the methods of the present invention.
The present application also discloses phytate salts (e.g., Na6IP6, Na5IP6, K4IP6, K6IP6, (NH4)6IP6)) prepared according to the methods of the present invention for use as a medicament. Also provided are uses of the phytate salts (e.g., Na6IP6, Na5IP6, K4IP6, K6IP6, (NH4)6IP6)) prepared according to the methods of the present invention for use in the treatment of a disease or condition disclosed herein, e.g., ectopic calcifications such as calciphylaxis or cardiovascular calcification. Also disclosed is the use of phytate salts (e.g., Na6IP6, Na5IP6, K4IP6, K6IP6, (NH4)6IP6)) prepared according to the methods of the present invention in the manufacture of a medicament for the treatment of a disease or condition disclosed herein, e.g., calciphylaxis or cardiovascular calcification.
In order that the present invention can be more readily understood, certain terms are first defined below. As used in this application, except as otherwise expressly provided herein, each of the following terms shall have the meaning set forth below. Additional definitions are set forth throughout the application.
The invention includes aspects in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The invention includes aspects in which more than one, or all the group members are present in, employed in, or otherwise relevant to a given product or process.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention is related. For example, the Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd Ed. (CRC Press, Boca Raton, FL, USA, 2002); The Dictionary of Cell and Molecular Biology, 3rd Ed. (Academic Press, London, UK, 1999); and the Oxford Dictionary of Biochemistry and Molecular Biology, Revised, (Oxford University Press, Oxford, UK, 2000), provide one of skill with a general dictionary of many of the terms used in this invention.
Units, prefixes, and symbols are denoted in their Système International de Unites (SI) accepted form. Numeric ranges are inclusive of the numbers defining the range. Where a range of values is recited, it is to be understood that each intervening integer value, and each fraction thereof, between the recited upper and lower limits of that range is also specifically disclosed, along with each subrange between such values. The upper and lower limits of any range can independently be included in or excluded from the range, and each range where either, neither or both limits are included is also encompassed within the invention.
Where a value is explicitly recited, it is to be understood that values which are about the same quantity or amount as the recited value are also within the scope of the invention. Where a combination is disclosed, each sub-combination of the elements of that combination is also specifically disclosed and is within the scope of the invention. Conversely, where different elements or groups of elements are individually disclosed, combinations thereof are also disclosed. Where any element of an invention is disclosed as having a plurality of alternatives, examples of that invention in which each alternative is excluded singly or in any combination with the other alternatives are also hereby disclosed; more than one element of an invention can have such exclusions, and all combinations of elements having such exclusions are hereby disclosed.
About: The term “about” as used herein to a value or composition that is within an acceptable error range for the particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined, i.e., the limitations of the measurement system. For example, “about” can mean within 1 or more than 1 standard deviation per the practice in the art. Alternatively, “about” can mean a range of up to 20%. Furthermore, particularly with respect to biological systems or processes, the terms can mean up to an order of magnitude or up to 5-fold of a value.
When particular values or compositions are provided in the application and claims, unless otherwise stated, the meaning of “about” should be assumed to be within an acceptable error range for that particular value or composition. When the term “about” is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. Thus, “about 10-20” means “about 10 to about 20.” In general, the term “about” can modify a numerical value above and below the stated value by a variance of, e.g., 10 percent, up or down (higher or lower).
And/or: “And/or” where used herein is to be taken as specific invention of each of the two specified features or components with or without the other. Thus, the term “and/or” as used in a phrase such as “A and/or B” herein is intended to include “A and B,” “A or B,” “A” (alone), and “B” (alone). Likewise, the term “and/or” as used in a phrase such as “A, B, and/or C” is intended to encompass each of the following aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
Approximately: As used herein, the term “approximately,” as applied to one or more values of interest, refers to a value that is similar to a stated reference value. In certain aspects, the term “approximately” refers to a range of values that fall within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).
Comprising: It is understood that wherever aspects are described herein with the language “comprising,” otherwise analogous aspects described in terms of “consisting of” and/or “consisting essentially of” are also provided.
Compound: As used herein, the term “compound,” is meant to include all isomers and isotopes of the structures depicted. As used herein, the term “isomer” means any geometric isomer, tautomer, zwitterion, stereoisomer, enantiomer or diastereomer of a compound. Compounds can include one or more chiral centers and/or double bonds and can thus exist as stereoisomers, such as double-bond isomers (i.e., geometric E/Z isomers) or diastereomers (e.g., enantiomers (i.e., (+) or (-)) or cis/trans isomers). The present invention encompasses any and all isomers of the compounds described herein, including stereomerically pure forms (e.g., geometrically pure, enantiomerically pure or diastereomerically pure) and enantiomeric and stereoisomeric mixtures, e.g., racemates. Enantiomeric and stereomeric mixtures of compounds and means of resolving them into their component enantiomers or stereoisomers are well-known. A compound, salt or complex of the present invention can be prepared in combination with solvent or water molecules to form solvates and hydrates by routine methods. In some aspects, the term compound is used to refer to a salt of inositol hexaphosphate (e.g., Na6IP6 or Na12IP6) of the present invention.
Inositol phosphate: As used herein, the term “inositol phosphate” (and grammatical variants thereof) refers to a compound with an inositol ring and one, two, three, four, five or six phosphate groups (i.e., IP1, IP2, IP3, IP4, IP5, IP6) or a combination thereof. The inositol phosphate may also include 7 or 8 phosphate groups (e.g., by attaching an additional phosphate group to a phosphate group already linked to the inositol ring). Myo-inositol hexaphosphate is an exemplary inositol hexaphosphate (IP6) of the present invention. In some aspects, the inositol phosphate is pure (e.g., over 99% of the inositol phosphate species are the same species, for example, IP6) or substantially pure (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% of the inositol phosphate species are the same species, for example, IP6). In some aspects, the inositol phosphate is a mixture, e.g., comprising variable amounts of IP1, IP2, IP3, IP4, IP5, IP6, IP7, and IP8. In some aspects, the inositol phosphate is a racemic mixture.
Inositol phosphate analog: A used herein, the term “inositol phosphate analog” (and grammatical variants thereof) refers to a compound that has a ring with different number of carbons with respect to an inositol ring (i.e., 5 or 7 carbons), and/or has at least one sulfate or thiophosphate group. For example, a compound comprising a ring with 5, 6 or 7 carbons and at least one phosphate, sulfate or thiophosphate group would be considered an inositol phosphate analog.
Inositol phosphate derivative: As used herein, the term “inositol phosphate derivative” (and grammatical variants thereof) refers to an “inositol phosphate” or “inositol phosphate analog” which has been derivatized with a heterologous moiety (i.e., a group that is not a phosphate, a sulfate or a thiophosphate). For example, an inositol pentasulfate comprising a heterologous moiety (e.g., PEG) would be considered inositol phosphate derivative.
Heterologous moiety: A used herein, the term “heterologous moiety” (and grammatical variants thereof) refers to a group or substituent in an inositol phosphate derivative which is not a phosphate, a sulfate or a thiophosphate, and confers a desirable property to such compound. For example, a heterologous moiety (e.g., a polyglycerol or a polyethyleneglycol) can increase the solubility of the compound. In some aspects, a heterologous moiety can confer multiple desirable properties, e.g., polyglycerol and polyethyleneglycol can both increase the solubility of a compound and reduce the clearance rate of the compound.
In some aspects, the inositol phosphate is an inositol phosphate, variant or derivative thereof disclosed in PCT/IB2018/057904, which describes compounds encompassed by formula I below.
Na6IP6: The term “Na6IP6” refers to the hexasodium salt of inositol hexaphosphate. In some aspects, Na6IP6 is a hexasodium salt of myo-inositol hexaphosphate.
Na12IP6: The term “Na12IP6” as used herein refers to the dodecasodium salt of inositol hexaphosphate. In some aspects, Na12IP6 is a dodecasodium salt of myo-inositol hexaphosphate.
Ph. Eur. 2.2.3.: The term “Ph. Eur. 2.2.3.” as used herein, refers to the “Potentiometric Determination of pH” measurement protocol [European Pharmacopeia 10.0, December 2020].
Ranges: As described herein, any concentration range, percentage range, ratio range or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one tenth and one hundredth of an integer), unless otherwise indicated.
Salt of inositol hexaphosphate: The terms “salt of inositol hexaphosphate disclosed herein” and “salt of inositol hexaphosphate of the present invention,” and grammatical variants thereof refers to a salt of inositol hexaphosphate (e.g., Na6IP6 or Na12IP6 or a combination thereof), prepared according to the methods disclosed herein. In some aspects, the salt is a sodium salt. In other aspects, the salt is a potassium salt (e.g., K6IP6 or K12IP6 or a combination thereof), prepared according to the methods disclosed herein. In other aspects, the salt is an ammonium salt (e.g., (NH4)6IP6 or (NH4)12IP6 or a combination thereof), prepared according to the methods disclosed herein. In some aspects, the salt of inositol hexaphosphate disclosed herein is Na6IP6 or Na12IP6 prepared according to the methods disclosed herein.
SNF472: As used herein, the term “SNF472” refers to an intravenous myo-inositol hexaphosphate formulation, e.g., a salt of inositol hexaphosphate (e.g., Na6IP6) disclosed herein. SNF472 is prepared at three different strengths: (i) 20 mg/mL in 5 mL single-use vials, (ii) 30 mg/mL in 5 mL and 10 mL single-use vials, and (iii) 90 mg/mL in 5 mL and 10 single-use vials. The product is formulated in a saline solution having a pH of about 5.6 to about 6.4.
Soluble: As used herein, the terms “soluble” and “solubility” refers to the degree to which a salt of an inositol phosphate dissolves in water to make an aqueous solution. A salt of an inositol phosphate (e.g., Na6IP6, Na5IP6, K4IP6, K6IP6, (NH4)6IP6)) is considered soluble in water provided that 1 g of the substance is dissolved in 10 to 30 mL of water or less at 15-25° C. See United States Pharmacopoeia (USP) and European Pharmacopoeia (EP) solubility criteria (e.g., USP, General Notices, 5.30 Description and Solubility (May 1, 2019) as measured according to USP <1236> (Dec. 1, 2019)).
Subject: By “subject” or “individual” or “animal” or “patient” or “mammal,” is meant any subject, particularly a mammalian subject, for whom diagnosis, prognosis or therapy is desired. Mammalian subjects include, but are not limited to, humans, domestic animals, farm animals, zoo animals, sport animals, pet animals such as dogs, cats, guinea pigs, rabbits, rats, mice, horses, cattle, cows; primates such as apes, monkeys, orangutans, and chimpanzees; canids such as dogs and wolves; felids such as cats, lions, and tigers; equids such as horses, donkeys, and zebras; bears, food animals such as cows, pigs, and sheep; ungulates such as deer and giraffes; rodents such as mice, rats, hamsters and guinea pigs; and so on. In certain aspects, the mammal is a human subject. In other aspects, a subject is a human patient. In a particular aspect, a subject is a human patient with a pathological calcification or at risk of having pathological calcifications. In some aspects, the subject is a human patient with a pathological calcification, for example an ectopic calcification such as a calciphylaxis calcification in need of treatment. In some aspects, the subject is a human patient with a cardiovascular calcification in need of treatment.
Substantially: As used herein, the term “substantially” refers to the qualitative condition of exhibiting total or near-total extent or degree of a characteristic or property of interest. One of ordinary skill in the biological arts will understand that biological and chemical phenomena rarely, if ever, go to completion and/or proceed to completeness or achieve or avoid an absolute result. The term “substantially” is therefore used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena.
Therapeutic agent: As used herein, the term “therapeutic agent” is used in a broad sense to include a composition comprising an inositol phosphate of the present invention, e.g., a salt of inositol hexaphosphate (e.g., Na6IP6 or Na12IP6) disclosed herein, that can provide a significant therapeutic benefit to a subject in need thereof, in particular, a subject suffering from or at risk of developing ectopic calcifications. Thus, a therapeutic agent according to the present invention can be, for example, (i) any salt of inositol hexaphosphate (e.g., Na6IP6, Na5IP6, K4IP6, K6IP6, (NH4)6IP6)) disclosed herein or a combination thereof or (ii) any dosage form, pharmaceutical composition or formulation disclose herein comprising a salt of inositol hexaphosphate (e.g., Na6IP6, Na5IP6, K4IP6, K6IP6, (NH4)6IP6)) disclosed herein or a combination thereof or (iii) a combination of a salt of inositol hexaphosphate (e.g., Na6IP6, Na5IP6, K4IP6, K6IP6, (NH4)6IP6)) disclosed herein or a combination thereof with one or more additional therapeutic agents, that is administered in an amount sufficient to effect beneficial or desired results.
The term therapeutic agent also encompasses prophylactic, diagnostic or imaging agents comprising a salt of inositol hexaphosphate (e.g., Na6IP6, Na5IP6, K4IP6, K6IP6, NH4)6IP6)) disclosed herein, wherein the therapeutic agent is administered, e.g., parenterally or topically. Therapeutic agents of the present invention include not only agents that treat ectopic calcifications or cardiovascular calcifications, but also agents that can ameliorate and/or prevent any symptom associated with the presence of a pathological calcification. Thus, as defined herein, the term therapeutic agent would include, for example, agents that can reduce or suppress inflammation, agent that increase the patient’s mobility, and agents that reduce pain.
Treating, treatment, therapy: As used herein, the terms “treating” or “treatment” or “therapy” refer to partially or completely alleviating, ameliorating, improving, relieving, delaying the onset of, inhibiting the progression of, reducing the severity of, reducing the incidence of one or more symptoms or features of disease or any combination thereof. For example, “treating” calciphylaxis can refer, e.g., to inhibiting calcification, reducing the size of calcification, increasing survival, increasing mobility, reducing pain or any combination thereof.
A treatment comprising a salt of inositol hexaphosphate (e.g., Na6IP6, Na5IP6, K4IP6, K6IP6, (NH4)6IP6)) disclosed herein can be administered to a subject who does not exhibit signs of a disease, disorder, and/or condition, and/or to a subject who exhibits only early signs of a disease, disorder, and/or condition for the purpose of, e.g., (i) decreasing the risk of developing a pathology associated with the disease, disorder, and/or condition, (ii) delaying the onset of the disease, disorder, and/or condition or a pathology associated with said disease, disorder, and/or condition or (iii) mitigating the symptoms and/or sequels of the disease, disorder, and/or condition or a pathology associated with said disease, disorder, and/or condition.
Thus, in general, the term “treatment” refers to countering the effects caused as a result of the disease or pathological condition of interest in a subject including (i) inhibiting the disease or pathological condition, in other words, slowing or stopping the development or progression thereof; (ii) relieving the disease or pathological condition, in other words, causing said disease or pathological condition or the symptoms thereof, to regress; (iii) stabilizing the disease or pathological condition, and (iv) any combination thereof.
The present invention provides processes for preparing soluble salts of inositol phosphates (IP) characterized by the formation of low levels of impurities during their execution. These processes improve the operability, scalability, reproducibility, and safety features of previously described processes for the preparation of Na6IP6. As a result, the processes of the invention yield an IP drug substance (e.g., Na6IP6) of high purity. The suitability of the IP drug substance so obtained for its use in human health and, particularly, for the treatment of various pathologies related to calcium crystallization is thus enhanced.
Recrystallization process: A key aspect of the methods to produce Na6IP6 disclosed herein is to use Na12IP6 purified via recrystallization as starting material in the Na6IP6 production process. Accordingly, the present invention provides a process for purifying an inositol phosphate (IP) salt, e.g., an unpurified soluble IP salt, the process comprising the steps of:
As used herein, the terms “IP solution,” “Na6IP6 solution,” and “Na12IP6 solution” refers to a composition comprising IP, Na6IP6 or Na12IP6 dissolved in a solvent, e.g., an aqueous solvent such as water. In general, the term “solution” means a liquid preparation that contains one or more soluble active ingredients (e.g., an IP of the present invention ) dissolved in a solvent.
As used herein, the terms “IP suspension,” “Na6IP6 suspension,” and “Na12IP6 suspension” refers to a composition comprising IP, Na6IP6 or Na12IP6 particles or crystals that are the result of the IP, Na6IP6 or Na12IP6 having fallen out of solution in the solvent, e.g., an aqueous solvent such as water. Accordingly, in the suspension the IP, Na6IP6 or Na12IP6 particles or crystals are suspended in the solvent. In general, the term “suspension” means a finely divided, undissolved active ingredient (e.g., an IP of the present invention ) suspended, i.e., not dissolved, in a solvent.
As used herein, the terms “IP solid,” “Na6IP6 solid,” or “Na12IP6 solid” refer to a mass, pellet or cake of IP, Na6IP6 or Na12IP6 resulting from the partial separation of the IP, Na6IP6 or Na12IP6 particles or crystals from the solvent, e.g., via centrifugation or via filtration.
As used herein, the terms “recrystallized IP salt,” “recrystallized Na6IP6,” or “recrystallized Na12IP6” refers to the purified product obtained after water has been removed from an IP solid, Na6IP6 solid or Na12IP6 solid, e.g., by drying.
In some aspects, the IP salt is of plant origin. Sources of IP salts (e.g., phytin) include, but are not limited to, species of the Cucurbitaceae, Fabaceae, Juglandaceae, Poaceae, Rosaceae, Rubiaceae, and Solanaceae families or combinations thereof. Examples of species belonging to the Cucurbitaceae family include, but are not limited to, varieties of the (a) Citrullus genus such as citron melon (C. caffer) and watermelon (C. lanutus), (b) Cucumis genus such as cucumber (C. sativus) (c) Cucurbita genus such as zucchini (C. pepo) and (d) Lagenaria genus such as calabash (L. siceraria). Examples of species belonging to the Fabaceae family include, but are not limited to, varieties of the (a) Arachis genus such as peanut (A. hypogaea) and pinto peanut (A. pintoi), (b) Ceratonia genus such as carob (C. siliqua), (c) Glycine genus such as soybean (G. max), (d) Glycyrrhiza genus such as liquorice (G. glabra) and American licorice (G. lepidota), (e) Lens genus such as lentil (L. culinaris), (f) Medicago genus such as alfalfa (M. sativa), (g) Phaseolus genus such as chickpeas (C. arietinum), white, pinto and black beans (P. vulgaris), and (h) Pisum genus such as pea (P. sativum). Examples of species belonging to the Juglandaceae family include, but are not limited to, varieties of the Juglans genus such as walnut (J. regia). Examples of species belonging to the Poaceae family include, but are not limited to, varieties of the (a) Avena genus such as oat (A. sativa) and (b) Oriza genus such as rice (O. sativa). Examples of species belonging to the Rosaceae and Rubiaceae families include, but are not limited to, varieties of the Prunus genus such as almonds (P. dulcis) and varieties of the Coffea genus such as coffee (C. arabica), respectively. Examples of species belonging to the Solanaceae family include, but are not limited to, varieties of the Solanum genus such as potato (S. tuberosum) and tomato (S. lycopersicum). In some aspects, the IP salt is obtained or derived from plant varieties modified genetically for (a) increasing the production of the IP salt, (b) increasing the purity of the IP salt, (c) facilitating the separation or extraction of the IP salt from the vegetable material or (d) reducing or silencing the expression of other compounds that may hinder the production or extraction of the IP salt from the vegetable material.
In some aspects, the IP salt is synthetized chemically or is obtained by processes that combine chemical and biological steps.
In some aspects, the Na12IP6 used in the Na6IP6 (
In some aspects, the Na12IP6 used in the Na6IP6 (
In some aspects of the recrystallization processes disclosed herein, the IP salt and water of step (i) are mixed in about a 1:1 to about 1:30 weight ratio. In some aspects of the recrystallization processes disclosed herein, the IP salt and water of step (i) are mixed in a 1:2 weight ratio. In some aspects, the IP salt and water of step (i) are mixed in a 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, 1:1.6, 1:1.7, 1:1.8, 1:1.9, 1:2, 1:2.1, 1:2.2, 1:2.3, 1:2.4, 1:2.5, 1:2.6, 1:2.7, 1:2.8, 1:2.9 or 1:3 weight/weight (w/w) ratio.
In some aspects of the recrystallization processes disclosed herein, the IP solution of step (i) is heated. In some aspects, the IP solution is heated at a temperature between about 40° C. and 50° C. In some aspects, the IP solution is heated at a temperature between about 41° C. and 49° C. In some aspects, the IP solution is heated at a temperature between about 42° C. and 48° C. In some aspects, the IP solution is heated at a temperature between about 43° C. and 47° C. In some aspects, the IP solution is heated at a temperature between about 44° C. and 46° C. In some aspects, the IP solution is heated at a temperature of about 38° C., about 39° C., about 40° C., about 41° C., about 42° C., about 43° C., about 44° C., about 45° C., about 46° C., about 47° C., about 48° C., about 49° C. or about 50° C.
In some aspects of the recrystallization processes disclosed herein, the IP solution is heated for about 4 hours or less. In some aspects, the IP solution is heated for about 2 hours or less. In some aspects, the IP solution is heated for about 0.2 hours, about 0.3 hours, about 0.4 hours, about 0.5 hours, about 0.6 hours, about 0.7 hours, about 0.8 hours, about 0.9 hours, about 1 hour, about 1.1 hours, about 1.2 hours, about 1.3 hours, about 1.4 hours, about 1.5 hours, about 1.6 hours, about 1.7 hours, about 1.8 hours, about 1.9 hours, about 2 hours, about 2.1 hours, about 2.2 hours, about 2.3 hours, about 2.4 hours, about 2.5 hours, about 2.6 hours, about 2.7 hours, about 2.8 hours, about 2.9 hours, about 3 hours, about 3.1 hours, about 3.2 hours, about 3.3 hours, about 3.4 hours, about 3.5 hours, about 3.6 hours, about 3.7 hours, about 3.8 hours, about 3.9 hours or about 4 hours. In some aspects, the IP solution is heated for between about 0.5 hours and about 1 hour, between about 1 hour and about 1.5 hours, between about 1.5 hours and about 2 hours, between about 2 hours and about 2.5 hours, between about 2.5 hours and about 3 hours, between about 3 hours and about 3.5 hours or between about 3.5 hours and about 4 hours.
In some aspects of the recrystallization processes disclosed herein, the IP solution is filtered, e.g., to remove insoluble impurities.
In some aspects of the recrystallization processes disclosed herein, the IP solution is seeded with crystals of the IP salt previously recrystallized. In some aspects, the IP solution is seeded with crystals representing about 0.4% (w/w) or less of the IP salt of step (i). In some aspects, the IP solution is seeded with crystals of the IP salt previously recrystallized representing about 0.1% (w/w) or less of the IP salt of step (i). In some aspects, the amount of crystal of the IP salt used for seeding is about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.09%, about 0.1%, about 0.11%, about 0.12%, about 0.13%, about 0.14%, about 0.15%, about 0.16%, about 0.17%, about 0.18%, about 0.19% or about 0.2%, about 0.21%, about 0.22%, about 0.23%, about 0.24%, about 0.25%, about 0.26%, about 0.27%, about 0.28%, about 0.29%, about 0.3%, about 0.31%, about 0.32%, about 0.33%, about 0.34%, about 0.35%, about 0.36%, about 0.37%, about 0.38%, about 0.39%, about 0.40% (w/w) or less of the IP salt of step (i).
In some aspects of the recrystallization processes disclosed herein, the IP solution is stirred. In some aspects of the recrystallization processes disclosed herein, the alcohol solution in step (iii) comprises, consists or consists essentially of a C1-C4 alcohol, e.g., methanol, ethanol, propanol, isopropanol, butanol or any combination thereof. In a specific aspect, the C1-C4 alcohol is ethanol.
In some aspects of the recrystallization processes disclosed herein, the drying of the solid of step (iv) is conducted at about 50° C. or less. In some aspects, the drying of the solid of step (iv) is conducted at about 45° C. or less. In some aspects, the drying of the solid of step (iv) is conducted at about 40° C. or less. In some aspects, the drying of the solid of step (iv) is conducted at about at about 20° C., about 21° C., about 22° C., about 23° C., about 24° C., about 25° C., about 26° C., about 27° C., about 28° C., about 29° C., about 30° C., about 31° C., about 32° C., about 33° C., about 34° C., about 35° C., about 36° C., about 37° C., about 38° C., about 39° C. or about 40° C., about 41° C., about 42° C., about 43° C., about 44° C., about 45° C., about 46° C., about 47° C., about 48° C., about 49° C. or about 50° C.
In some aspects, drying is conducted during about 25 minutes, about 30 minutes, about 35 minutes, 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, about 65 minutes, about 70 minutes, about 75 minutes, about 80 minutes, about 85 minutes, about 90 minutes, about 95 minutes, about 100 minutes, about 105 minutes, about 110 minutes, about 115 minutes or about 120 minutes.
In some aspects, drying is conducted under vacuum. In some aspects, drying is conducted under a pressure of about 1 mbar, about 0.9 mbar, about 0.8 mbar, about 0.7 mbar, about 0.6 mbar, about 0.5 mbar, about 0.4 mbar, about 0.3 mbar, about 0.2 mbar, about 0.1, about 0.09 mbar, about 0.08 mbar, about 0.07 mbar, about 0.06 mbar, about 0.05 mbar, about 0.04 mbar, about 0.03 mbar, about 0.02 mbar or about 0.01 mbar. In some aspects, drying is conducted under a pressure of below about 1 mbar, below about 0.9 mbar, below about 0.8 mbar, below about 0.7 mbar, below about 0.6 mbar, below about 0.5 mbar, below about 0.4 mbar, below about 0.3 mbar, below about 0.2 mbar, below about 0.1, below about 0.09 mbar, below about 0.08 mbar, below about 0.07 mbar, below about 0.06 mbar, below about 0.05 mbar, below about 0.04 mbar, below about 0.03 mbar, below about 0.02 mbar or below about 0.01 mbar. In a particular aspect, drying is conducted at approx. 40° C., at approx. 1 mbar, for about 60 minutes. In other particular aspects, drying is conducted at approx. 25° C., at approx. 0.01 mbar, for about 90 minutes.
The person skilled in the art knows that simultaneous changes to the temperature, duration, and pressure conditions of step (iv) could yield a product of similar characteristics (e.g., by reducing pressure and temperature while and increasing the duration of the drying step). For instance, the temperature and pressure in step (iv) could be set at 25° C. and 1 mbar, respectively, for 88 minutes, to obtain a level of impurities (0.52% w/w) which is also attained when this step is conducted at 40° C. and 0.01 mbar for 64 minutes. These combinations of temperature, duration and pressure are considered within the scope of the present invention and the common sense of the person skilled in the art.
In some aspects, the recrystallization process of the present invention can be used to produce a starting material or intermediate for the production of another form of the IP. For example, Na12IP6 recrystallized according to the processes disclosed herein can be used to produce Na6IP6. In other aspects, one or more iterations of the recrystallization processes disclosed herein can be used to increase the purity of an IP. Thus, for example, Na6IP6 produced according to the methods disclosed herein can be further purified by the application of one or more cycles of recrystallization disclosed herein to improve the purity of the final product.
The recrystallization processes disclosed herein are characterized by using an IP (e.g., Na12IP6, Na6IP6, K12IP6 or K6IP6) as the starting IP material and:
Soluble IP salt preparation processes: The present invention also provides processes for preparing a soluble salt of an inositol phosphate (IP), e.g., a sodium salt of IP6 (phytate) such as Na6IP6.
In some aspects, the process for preparing a soluble IP salt comprises:
Schematic representations of the processes disclosed herein are provided in
Thus, the invention provides a soluble IP salt preparation process which comprises the removal of all cations (e.g., Na+, K+, NH4+) from the starting material or intermediate (e.g., Na12IP6, Na10IP6, K6IP6, K12IP6, (NH4)12IP6)) by using an ion-exchange medium, the resulting acid form of the IP (e.g., phytic acid) is concentrated to yield a syrup, and the syrup is subsequently treated with an alkoxide (e.g., a methoxide such as sodium methoxide) under precise ratio and pH conditions. Cations from the alkoxide interact with the IP acid to yield a purified IP salt product with the desired cation: IP stoichiometry (e.g., Na6IP6, in which the sodium/phosphate ratio is 1:1).
Whereas the original manufacturing process was a 2-step process (See
In some specific aspects of the invention, the soluble IP salt preparation process is directed to the preparation of Na6IP6. Accordingly, in some aspects, the present invention provides a soluble IP salt preparation process comprising:
In some aspects, the ion exchange medium of step (b) is conducted in an ion exchange chromatography system (e.g., in a column), (ii) an ion exchange batch process or (iii) a pH adjustment system.
The term “ion exchange chromatography” or “IXC” as used herein, refers to process for separating molecules based on their differences in net surface charge. IXC takes advantage of the fact that the relationship between net surface charge and pH is unique for a specific molecule. In an IXC separation, reversible interactions between charged molecules and oppositely charged IXC media are controlled in order to favor binding or elution of specific molecules and achieve separation. An IXC medium comprises a matrix of spherical particles substituted with ionic groups that are negatively or positively charged. The matrix is usually porous to give a high internal surface area. The medium could be packed into a column to form a packed bed. The bed is then equilibrated with buffer which fills the pores of the matrix and the space in between the particles. See Ninfa A, et al., Fundamental Laboratory Approaches for Biochemistry and Biotechnology (John Wiley & Co, Hoboken, NJ, USA, 2010).
The terms “ion exchange batch process” or “batch process” as used herein, relates to an ion exchange separation technique wherein the separation occurs in a closed system (e.g, reactor). Thus, the inflow of additional analyte through the matrix, as in an ion exchange column, is not available. In this technique, the ion exchange matrix and the analyte solution are mixed in a batch vessel until they reach an equilibrium. Then, the matrix is filtered off from the solution, washed and regenerated in a special system to collect the molecule of interest.
The term “pH adjustment system” as used herein, refer to the use of changes in the pH of an analyte solution for modulating the strength with which a molecule of interest attaches to an ion exchange matrix. This manipulation could allow the identification and release at will of the molecule of interest.
In some aspects, the IP solution of steps (a) and (b) comprises, consists or consists essentially of a dodecasodium salt of IP (e.g., Na12IP6). In other aspects, the IP solution of steps (a) and (b) comprises, consists or consists essentially of a decasodium salt of IP (e.g., Na10IP6), hexapotassium salt of IP (e.g., K6IP6), dodecapotassium salt of IP (e.g., K12IP6) or a dodecammonium salt of IP (e.g., (NH4)12IP6). In other aspects, the IP solution of steps (a) and (b) comprises, consists or consists essentially of a hexasodium salt of IP (e.g., Na6IP6). In other aspects, the IP solution of steps (a) and (b) comprises, consists or consists essentially of a tetrapotassium salt of IP (e.g., K4IP6), pentasodium salt of IP (e.g., Na5IP6), hexapotassium salt of IP (e.g., K6IP6) or a hexammonium salt of IP (e.g., (NH4)6IP6).
In some aspects, the ion exchanged IP solution obtained from step (b) and the IP syrup of step (c) comprise, consist or consist essentially of a hexasodium salt of IP (e.g., Na6IP6). In other aspects, the ion exchanged IP solution obtained from step (b) and the IP syrup of step (c) comprise, consist or consist essentially of a tetrapotassium salt of IP (e.g., K4IP6), pentasodium salt of IP (e.g., Na5IP6), hexapotassium salt of IP (e.g., K6IP6) or a hexammonium salt of IP (e.g., (NH4)6IP6).
In some aspects, the concentration of step (c) is conducted by distilling the IP solution at about 55° C. or less. In some additional aspects, step (c) is conducted by distilling the IP solution at about 25° C. to about 55° C. In some further aspects, step (c) is conducted by distilling the IP solution at about 40° C. to about 45° C. In some further aspects, step (c) is conducted by distilling the IP solution at about 40° C.
In some aspects, the concentration of step (c) is conducted by distilling the IP solution at about 25° C., about 26° C., about 27° C., about 28° C., about 29° C., about 30° C., about 31° C., about 32° C., about 33° C., about 34° C., about 35° C., about 36° C., about 37° C., about 38° C., about 39° C. or about 40° C., about 41° C., about 42° C., about 43° C., about 44° C., about 45° C., about 46° C., about 47° C., about 48° C., about 49° C. or about 50° C., about 51° C., about 52° C., about 53° C., about 54° C. or about 55° C. In some aspects, the concentration of step (c) is conducted by distilling the IP solution at a temperature below about 40° C., below about 39° C., below about 38° C., below about 37° C., below about 36° C., below about 35° C., below about 34° C., below about 33° C., below about 32° C., below about 31° C., below about 30° C., below about 29° C., below about 28° C., below about 27° C., below about 26° C. or below or about 25° C. In some aspects, the concentration of step (c) is conducted by distilling the IP solution at a temperature between about 20° C. and about 25° C., between about 25° C. and about 30° C., between about 30° C. and about 35° C., between about 35° C. and about 40° C., between about 40° C. and about 45° C., between about 45° C. and about 50° C. or between about 50° C. and about 55° C.
In some aspects, the concentration of step (c) is conducted by distilling the IP solution for about 16 hours or less. In some aspects, the concentration of step (c) is conducted by distilling the IP solution for about 1 hour to about 16 hours. In some aspects, the concentration of step (c) is conducted by distilling the IP solution for about 12 hours to about 14 hours. In some aspects, the concentration of step (c) is conducted by distilling the IP solution for about 16 hours, for about 15 hours, for about 14 hours, about 13 hours, about 12 hours, about 11 hours, about 10 hours, about 9 hours, about 8 hours, about 7 hours, about 6 hours, about 5 hours, about 4 hours, about 3 hours, about 2 hours or about 1 hour. In some aspects, the concentration of step (c) is conducted by distilling the IP solution for about 1 hour to about 2 hours, about 2 hours to about 3 hours, about 3 hours to about 4 hours, about 4 hours to about 5 hours, about 5 hours to about 6 hours, about 6 hours to about 7 hours, about 7 hours to about 8 hours, about 8 hours to about 9 hours, about 9 hours to about 10 hours, about 10 hours to about 11 hours, about 11 hours to about 12 hours, about 12 hours to about 13 hours, about 13 hours to about 14 hours, about 14 hours to about 15 hours or about 15 hours to about 16 hours.
In some aspects, the concentration of step (c) is conducted by distilling the IP solution under vacuum. In some aspects, the concentration of step (c) is conducted by distilling the IP solution under vacuum at a pressure of about 1 mbar, about 0.9 mbar, about 0.8 mbar, about 0.7 mbar, about 0.6 mbar, about 0.5 mbar, about 0.4 mbar, about 0.3 mbar, about 0.2 mbar, about 0.1, about 0.09 mbar, about 0.08 mbar, about 0.07 mbar, about 0.06 mbar, about 0.05 mbar, about 0.04 mbar, about 0.03 mbar, about 0.02 mbar or about 0.01 mbar. In some aspects, the concentration of step (c) is conducted by distilling the IP solution under vacuum at a pressure below about 1 mbar, below about 0.9 mbar, below about 0.8 mbar, below about 0.7 mbar, below about 0.6 mbar, below about 0.5 mbar, below about 0.4 mbar, below about 0.3 mbar, below about 0.2 mbar, below about 0.1, below about 0.09 mbar, below about 0.08 mbar, below about 0.07 mbar, below about 0.06 mbar, below about 0.05 mbar, below about 0.04 mbar, below about 0.03 mbar, below about 0.02 mbar or below about 0.01 mbar.
In some aspects, the water content of the IP syrup is between about 30% and 60% (w/w). In some aspects, the water content of the IP syrup is between about 40% and about 45% (w/w). As used herein, the term “syrup” refers to a concentrated solution of an IP salt of the present invention (e.g., Na6IP6). In some aspects, the water content of the IP syrup is at least about 40% (w/w), at least about 41% (w/w), at least about 42% (w/w), at least about 43% (w/w), at least about 44% (w/w), at least about 45% (w/w), at least about 46% (w/w), at least about 47% (w/w), at least about 48% (w/w), at least about 49% (w/w), at least about 50% (w/w), at least about 51% (w/w), at least about 52% (w/w), at least about 53% (w/w), at least about 54% (w/w), at least about 55% (w/w), at least about 56% (w/w), at least about 57% (w/w), at least about 58% (w/w), at least about 59% (w/w) or at least about 60% (w/w).
In some aspects, the water content of the IP syrup is about 40% (w/w), about 41% (w/w), about 42% (w/w), about 43% (w/w), about 44% (w/w), about 45% (w/w), about 46% (w/w), about 47% (w/w), about 48% (w/w), about 49% (w/w), about 50% (w/w), about 51% (w/w), about 52% (w/w), about 53% (w/w), about 54% (w/w), about 55% (w/w), about 56% (w/w), about 57% (w/w), about 58% (w/w), about 59% (w/w) or about 60% (w/w).
In some aspects, the water content of the IP syrup is between about 40% and about 45% (w/w). In some aspects, the water content of the IP syrup is between about 40% and about 42% (w/w), about 42% and about 44% (w/w), about 44% and about 46% (w/w), about 46% and about 48% (w/w), about 48% and about 50% (w/w), about 50% and about 52% (w/w), about 52% and about 54% (w/w), about 54% and about 56% (w/w), about 56% and about 58% (w/w) or about 58% and about 60% (w/w). In some aspects, the water content of the IP syrup is between about 45% and about 50% (w/w), about 50% and about 55% (w/w) or about 55% and about 60% (w/w).
In some aspects, the alkoxide is a C1-C4 alkoxide (e.g., methoxide, ethoxide, ter-butoxide, isoproxide or any combination thereof). In some aspects, the alkoxide is sodium methoxide, potassium methoxide, sodium ethoxide, potassium ethoxide, sodium ter-butoxide, potassium ter-butoxide, sodium isoproxide, potassium isoproxide or any combination thereof. In some aspects, the C1-C4 alkoxide is CH3NaO, CH3CH2NaO, CH3KO, CH3CH2KO or any combination thereof.
In some aspects, step (d) is conducted at a pH between about pH 4.0 and about pH 5.5. In some aspects, step (d) is conducted at a pH of about 4.0, about 4.1, about 4.2, about 4.3, about 4.4, about 4.5, about 4.6, about 4.7, about 4.8, about 4.9, about 5.0, about 5.1, about 5.2, about 5.3, about 5.4 or about 5.5. In some aspects, step (d) is conducted at a pH between about pH 4.1 and about pH 5.4, between about pH 4.2 and about pH 5.3, between about pH 4.3 and about pH 5.2, between about pH 4.4 and about pH 5.1, between about pH 4.5 and about pH 5.0, between about pH 4.6 and about pH 4.9, between about pH 4.7 and about pH 4.8. In some aspects, step (d) is conducted at a pH between about pH 4.0 and about pH 4.5, between about pH 4.5 and about pH 5.0, between about pH 5.0 and about pH 5.5, between about pH 4.4 and about pH 4.7, between about pH 4.3 and about pH 4.6, between about pH 4.4 and about pH 4.8 or between about pH 4.5 and about pH 4.9.
In some aspects, the ethanol is added to the IP syrup (e.g., IP6 syrup) in step (d), followed by the addition of the alkoxide (e.g., sodium methoxide), which causes the precipitation of the soluble IP salt (e.g., Na6IP6). In some aspects, the precipitated soluble IP salt (e.g., Na6IP6) is re-slurried by the addition of acetone (e.g., 2 volumes of acetone).
In some aspects, the process for preparing a soluble salt of an inositol phosphate (IP) described above further comprises a step (e) wherein the soluble IP salt of step (d) is dried. In some aspects, the drying of step (e) comprises spray drying. In some aspects, the soluble IP salt of step (d) is purified.
In some aspects, the soluble IP salt of step (a) has been previously purified according to the recrystallization processed disclosed above. In some aspects, the soluble IP salt of steps (d) or (e) is further purified according to the recrystallization processes disclosed above.
In some aspects of the processes disclosed herein, the IP contains between 1 and 6 phosphate groups. In some aspects, the IP contains between 7 or 8 phosphate groups (e.g., a phosphate group is attached to another phosphate group already linked to the inositol phosphate scaffold). In some aspects, the IP consists or consists essentially of inositol hexaphosphate. In some aspects, the inositol hexaphosphate is myo-inositol hexaphosphate.
In some aspects, the IP salt (e.g., a salt of myo-inositol hexaphosphate) contains at least one monovalent cation. In some aspects, the IP salt contains at least one Group 1 alkali metal element cation (e.g., Na+ or K+). In some aspects, the IP salt contains at least one ammonium cation (i.e., NH4+). In some specific aspects, the Group 1 alkali metal element is sodium. In other aspects, the Group 1 alkali metal element is potassium. In some aspects, the Group 1 alkali metal element is a combination of sodium and potassium. In some aspects, the ratio of sodium to potassium, e.g., in a salt of myo-inositol hexaphosphate, is 1:5, 2:4, 3:3, 4:2 or 5:1 (sodium:potassium).
The present invention provides purified soluble IP salts obtained according to the processes described above. In some aspects, the purified soluble IP salt is a monovalent cationic salt of inositol hexaphosphate (e.g., Na6IP6, Na5IP6, K4IP6, K6IP6, (NH4)6IP6). In a particular aspect, the purified soluble IP salt is Na6IP6.
The present invention provides also IP6 salts with specific degrees of purity and specific impurity profiles which are characteristic of the IP6 salts prepared according to the process disclosed herein. Accordingly, the present invention provides an IP6 salt that is at least 70% (w/w) pure characterized for comprising:
Also provided is an IP6 salt that is at least 80% (w/w) pure characterized for comprising:
In some aspects, the IP6 salts above are sodium IP6 salts. In some further aspects, the IP6 salt is a hexasodium IP6 salt.
In some aspects, the present invention provides a process to produce a purified IP soluble salt, wherein the process comprises:
In-process control tests (IPCs) conducted during the manufacturing processes described herein are intended to provide a means of monitoring product purity, yield and integrity and have evolved along time as more experience and information have been gained from process development and optimization.
In some aspects, the present invention provides a process of preparing a soluble IP salt, e.g., Na6IP6, wherein the process comprises several internal process control points (IPC 1-9) wherein said tests are performed to optimize the output of the process. See
In some aspects, the present invention provides a process of preparing a purified soluble IP salt, e.g., Na6IP6, Na5IP6, K4IP6, K6IP6, (NH4)6IP6, wherein the process comprises several internal process control points (IPC 1-5B) wherein said tests are performed to optimize the output of the process. See
Accordingly, the present invention provides a process of preparing a purified soluble IP salt, e.g., Na6IP6, Na5IP6, K4IP6, K6IP6, (NH4)6IP6), such as any of the processes comprising steps (a)-(d) or (a)-(e) disclosed above, in some aspects further comprising a recrystallization process disclosed herein, wherein the process comprises the disclosed internal process control points (IPC) and acceptance criteria or any combination thereof.
The present invention also provides pharmaceutical compositions comprising an IP salt produced according to any of the processes disclosed herein, e.g., Na6IP6 salt prepared according to any one of the methods disclosed or a mixture of those salts. In some aspects, the pharmaceutical composition pharmaceutical composition is injectable. In some aspects, the pharmaceutical composition is administered parenterally. In some aspects, the parenteral administration is intravenous. In some aspects, the intravenous administration is by bolus injection. In some aspects, the intravenous administration is via intravenous infusion.
The present invention also provides combination treatments comprising (i) compositions comprising an IP salt produced according to any of the processes disclosed herein, e.g., Na6IP6 salt prepared according to any one of the methods disclosed or a mixture of those salts, and (ii) at least a second therapeutic agent or treatment.
The present invention also provides a kit or article of manufacture comprising (i) compositions comprising an IP salt produced according to any of the processes disclosed herein, e.g., Na6IP6 salt prepared according to any one of the methods disclosed or a mixture of those salts, and (ii) instructions for use, e.g., instruction for administration to a subject in need thereof.
The present invention also provides methods for treating or preventing ectopic calcification or its consequences in a subject in need thereof comprising administering a composition comprising a therapeutic or prophylactic agent comprising an IP salt (e.g., Na6IP6) prepared according to any of the processes disclosed herein or a mixture of those salts. In some aspects, the subject is undergoing hemodialysis. In some aspects, the subject has end-stage renal disease.
In some aspects of the present invention, the processes disclosed herein and variants thereof can be used to obtain other inositol phosphate (IP) salts with a high degree of purity. For example, for an inositol phosphate IP1 to IP6 of formula AxIPy, wherein (i) A is a monovalent cation such as an alkali cation (e.g., Na+ or K+), ammonium (i.e., NH4+) or a combination thereof), (ii) y is an integer between 1 and 6, and (iii) x is an integer between 1 and 12, which can be used to generate an inositol phosphate of formula BzIPy, via a process where the compound of formula AxIPy is recrystallized from a source material, and is processed to yield the compound of formula BzIPy, where z is an integer between 1 and 12. In some aspects, B can be the same as A (i.e., the starting material and the final product have the same monovalent cation) or not (i.e., the starting material and the final product have different monovalent cations).
In some aspects, the compound of formula AxIPy can be a hexacyclic (inositol) ring, however, other ring sizes are contemplated (e.g., 5 or 7 carbon rings), as well as hexacyclic rings having more than 6 phosphate groups (e.g., IP7, IP8), as disclosed elsewhere. In some aspects, P in the formula above can be phosphate, sulfate, thiophosphate or any combination thereof.
Accordingly, in some aspects, the inositol phosphates of the present invention comprise pharmaceutically acceptable salts (e.g., sodium salts or potassium salts) of compounds of formula I, a thereof or a combination thereof, prepared according to the methods disclosed herein, e.g., Na6IP6:
wherein
The formulas disclosed herein are meant to encompass any diastereomer.
In some aspects, at least one of R1, R3, R5, R7, R9 and R11 independently represents H, -X, -OX, -NHX, -NX2, -SX, -OSO3HX, -OSO3X2 or a compound of formula II, formula III or formula IV, where each X independently represents H, C1-30 alkyl, C2-30 alkenyl, C2-30 alkynyl or Cy1, where C1-30 alkyl, C2-30 alkenyl and C2-30 alkynyl are independently optionally substituted with one or more R14 and where Cy1 is optionally substituted by one or more R15; Cy1 represents a carbocyclic or heterocyclic three- to 10-membered ring, which can be saturated, partially unsaturated or aromatic, where said heterocycle has between one and four heteroatoms selected from amongst O, S and N, where said ring can be bound to the rest of the molecule via any available C atom and where Cy1 is optionally fused to between one and four five- or six-membered rings, each saturated, partially unsaturated or aromatic, carbocyclic or heterocyclic, and where said fused heterocycle can contain one or two heteroatoms selected from amongst O, N and S; each R13 independently represents H, C1-30 alkyl, — NH2, —NHC1-30alkyl or N(C1-30alkyl)2, where each C1-30 alkyl is independently optionally substituted with one or more halogen, —OH, —CN and —NO2 groups; and each R14 and R15 independently represents —OH, C1-30 alkoxy, C1-30 alkyithionyl, C1-30 acyloxy, phosphate, halogen, trihalo C1-30 alkyl, nitrile azide.
In some aspects, each X independently represents H, C1-30 alkyl or Cy1, where C1-30 alkyl is optionally substituted by one or more R14 and where Cy1 is optionally substituted by one or more R15; and each R14 and R15 independently represents —OH, C1-30 alkoxy, C1-30 alkyithionyl, C1-30 acyloxy, phosphate, halogen, trihaloC1-30alkyl, nitrile or azide. In some aspects, each X represents H, C1-30alkyl or Cy1. In some aspects, each X represents H.
In some aspects, at least one of radicals R1, R3, R5, R7, R9 and R11 independently represents a compound of formula II, formula III or formula IV, each R13 independently represents H, C1-30 alkyl, —NH2, —NHC1-30 alkyl or —N(C1-30 alkyl)2, where each C1-30 alkyl is independently optionally substituted by one or more halogen, — OH, —CN and —NO2 groups; and R2, R4, R6, R8, R10 and R12 independently represent H.
In another aspect, R1, R3, R5, R7, R9 and R11 independently represent a compound of formula II, formula III or formula IV, each R13 independently represents H or C1-30alkyl, where each C1-30alkyl is independently optionally substituted by one or more halogen, —OH, —CN and —NO2 groups; and R2, R4, R6, R8, R10 and R12 independently represent H.
In another aspect, R1, R3, R5, R7, R9 and R11 independently represent a compound of formula II, formula III or formula IV, each R13 independently represents H or C1-30alkyl; and R2, R4, R6, R8, R10 and R12 independently represent H.
In another aspect, R1, R3, R5, R7, R9 and R11 independently represent a compound of formula II, formula III or formula IV, each R3 independently represents H; and R2, R4, R6, R8, R10 and R12 independently represent H.
In a particular aspect, the compound is inositol hexaphosphate (IP6). In some aspects, compound comprises an IP4 or IP5. Inositol is assumed to mean any isomeric form of the molecule.
All compounds of formula I contain C—O—P or C—O—S bonds, which provide the compounds with an affinity for calcium-containing crystals and a sufficiently labile bond to be hydrolyzed in vivo, thereby preventing irreversible binding to calcium-containing crystals such as the hydroxyapatite (HAP) in bone, which would have a negative impact on bone remodeling, as is the case with bisphosphonates when administered long term as said compounds contain P—C—P bonds that cannot be hydrolyzed by the body. At the other extreme are phosphorylated compounds that do not contain said C—O—P bonds, such as pyrophosphates, the P—O—P bonds of which mean that they are too readily hydrolyzed in the intestine, thus meaning that only parenteral administration is feasible.
The compounds of the present invention, with C—O—P bonds, C—O— S bonds, and combinations thereof represent an adequate midpoint due to the efficacy thereof and the fact that the body presents mechanisms for eliminating said compounds, thus reducing the risk of side effects (e.g., compounds with P—C—P bonds can present half-lives of several months which in vivo, thereby affecting, e.g., bone remodeling).
The term “alkyl” or “alkyl group” in the context of the present invention refers to a saturated hydrocarbon moiety, which can be linear, branched, cyclic or cyclic with linear or branched side chains. The term alkyl includes partially unsaturated hydrocarbons such as propenyl. Examples are methyl, ethyl, n- or isobutyl, n- or cyclohexyl. The term alkyl can extend to alkyl groups linked or bridged by hetero atoms. Hetero atoms in the context of the present invention are nitrogen (N), sulfur (S) and oxygen (O).
An “amine function” or “amine group” is a function NR′R″, with R′ and R″ selected independently from hydrogen and C1-C5 alkyl. In some embodiments, R′ and R″ are selected from hydrogen and C1-C3 alkyl. A “hydroxy function” or “hydroxy group” is OH. A “thiol function” or “thiol group” is SH. A “carboxylic acid function” or “carboxylic acid group” is COOH or its anion, COO-. A “carboxylic amide” is CONR′R″, with R′ and R″ independently having the meanings indicated above. A “sulfonic acid” is SO3H. A “sulfonic acid amide” is SO2NR′R”, with R′ and R″ independently having the meanings indicated above.
A “C1-C3 alkyl” in the context of the present invention refers to a saturated linear or branched hydrocarbon having 1, 2 or 3 carbon atoms, wherein one carbon-carbon bond can be unsaturated and one CH2 moiety can be exchanged for oxygen (ether bridge). Non-limiting examples for a C1-C3 alkyl are methyl, ethyl, propyl, prop-2-enyl and prop-2-inyl.
A “C1-C5 alkyl” in the context of the present invention refers to a saturated linear or branched hydrocarbon having 1, 2, 3, 4 or 5 carbon atoms, wherein one or two carbon-carbon bond can be unsaturated and one CH2 moiety can be exchanged for oxygen (ether bridge). Non-limiting examples for a C1-C5 alkyl include the examples given for C1-C3 alkyl above, and additionally n-butyl, 2-methylpropyl, tert-butyl, 3-methylbut-2-enyl, 2-methylbut-3-enyl, 3-methylbut-3-enyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1,2-dimethylpropyl, but-3-enyl, but-3-inyl and pent-4-inyl.
A “C3-C10 alkyl” in the context of the present invention refers to a saturated linear or branched hydrocarbon having 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, wherein 1, 2 or 3 carbon-carbon bonds can be unsaturated and one CH2 moiety can be exchanged for oxygen (ether bridge).
The term “C1-30 alkyl,” as a group or part of a group, refers to a linear or branched chain alkyl group containing between 1 and 30 carbon atoms including, amongst others, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, decyl and dodecyl groups.
The term “C2-30 alkenyl” refers to a linear or branched alkyl chain containing between 2 and 30 carbon atoms and also contains one or more double bonds. Examples include, amongst others, ethenyl, 1-propenyl, 2-propenyl, isopropenyl 1-butenyl, 2-butenyl, 3-butenyl and 1,3-butadienyl.
The term “C2-30 alkynyl” refers to a linear or branched alkyl chain containing between 2 and 30 carbon atoms and also contains one or more triple bonds. Examples include, amongst others, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl and 1,3-butadiynyl.
A “Cy1 group” refers to a three- to 10-membered carbocyclic or heterocyclic ring that can be saturated, partially unsaturated or aromatic and which is bound to the rest of the molecule via any available C atom. When heterocyclic, Cy1 contains between one and four heteroatoms selected from amongst N, O and S. Moreover, Cy1 can optionally be fused with up to four five- or six-membered carbocyclic or heterocyclic rings, which can be saturated, partially unsaturated or aromatic.
If the fused ring is a heterocycle, said ring contains one or two heteroatoms selected from amongst N, O and S. Examples of Cy1 include, amongst others, phenyl, naphthyl, thienyl, furyl, pyrrolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, 1,3,4-thiadiazolyl, 1,2,4-thiadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, benzimidazolyl, benzofuranyl, isobenzofuranyl, indolyl, isoindolyl, benzothiophenyl, benzothiazolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, azetidinyl and aziridinyl.
A “C1-30 alkoxy group,” as a group or part of a group, refers to a —OC1—30alkyl group, where the C1-30alkyl part has the same meaning as above. Examples include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, and tert-butoxy.
A “C1-30 alkylthionyl group” as a group or part of a group refers to an — SOC1-30alkyl group, where the C1-30alkyl part has the same meaning as above. Examples include methylthionyl, ethylthionyl, propyithionyl, isopropyithionyl, butylthionyl, isobutyithionyl, sec-butylthionyl, and tert-butylthionyl.
A “C1-30 acyloxy group” as a group or part of a group refers to a —COC1-30alkyl group, where the C1-30alkyl part has the same meaning as above. Examples include acetyl, ethanoyl, propanoyl and 2,2-diisopropylpentanoyl.
A “halogen radical” or the halo abbreviation thereof refers to fluorine, chlorine, bromine, and iodine.
A “trihalo C1-30 alkyl group” refers to a group resulting from the substitution of three hydrogen atoms of a C1-30alkyl group by three halogen radicals as defined above. Examples include, amongst others, trifluoromethyl, tribromomethyl, trichloromethyl, triiodomethyl, trifluoroethyl, tribromoethyl, trichloroethyl, triiodoethyl, tribromopropyl, trichloropropyl, and triiodopropyl.
An “—NHC1-30 alkyl group” refers to a group resulting from the substitution of one hydrogen atom of an —NH2 group by a C1-30alkyl group as defined above. Examples include, amongst others, methylamine, ethylamine, propylamine, butylamine, and pentylamine.
An “—N(C1-30alkyl)2group” refers to a group resulting from the substitution of two hydrogen atoms of an —NH2 group by a C1-30alkyl group as defined above. Examples include, amongst others, dimethylamine, diethylamine, diisopropylamine, dibutylamine, and diisobutylamine.
The expression “optionally substituted by one or more” signifies the possibility that a group can be substituted by one or more, e.g., by 1, 2, 3 or 4 substituents. In some aspects, a group can be substituted by 1, 2 or 3 substituents and even by 1 or 2 substituents provided that the group has sufficient positions that can be substituted available. If present, the substituents can be the same or different and can be located at any available position.
In some aspects, the inositol phosphates of the present invention used, e.g., in the methods of manufacture and compositions disclosed herein, comprise salts (e.g., sodium or potassium salts) of the compounds disclosed in WO2017098033 and WO2017098047, and US9358243.
In some aspects, the inositol phosphates, inositol phosphate analogs, and derivatives thereof used, e.g., in the methods and compositions disclosed herein, comprise compounds of formula (V), formula (VI) or formula (VII):
wherein
In some aspects, Z, as used in formula (V), is CH2, CHX, CHR1, CXR1, CH2—CH2, CH2—CHX, CHX-CHX, CHR1-CHX, CXR1-CHX, CHR1-CH2, CXR1-CH2, CHR1—CHOH, CH2—CH2—CH2, CH2—O—CH2, CHOH—CH2—CH2, CHOH—CHOH—CHR1, CHOH—CHR1-—CHOH, CHX—CH2—CH2, CH2—CHX— CH2, CHX—CHX—CH2, CHX—CH2—CHX or CHX—CHR1—CHX, wherein X independently is selected from OPO32-, OPSO22-, and OSO3-.
In some aspects, Z, as used in formula (V), is (CHX)pCHX(CHX)q; wherein p and q each independently from the other have a value from 0 to 2, with the proviso that (p+q) has a value of 0, 1 or 2; one or two or three X can be a heterologous moiety (e.g., PEG) and the remaining X are independently selected from OPO32-, OPSO22-, and OSO3-. In some aspects, not all X of Z are OPO32-. In some aspects, not all X of Z are OSO3-.
In some aspects, one, two or three of the X in compounds of formula (V), formula (VI) or formula (VII) can be heterologous moiety and the remaining X can independently be selected from OPO32-, OPSO22- or OSO3-.
Formula (V) above describes a five-membered, six-membered or seven-membered alkyl ring, and the optional heterologous moiety or moieties is/are attached to one of the carbon atoms forming the ring.
In some aspects, the inositol phosphates, inositol phosphate analogs, and derivatives thereof used, e.g., in the methods of manufacture and compositions disclosed herein, comprise compounds of formula (VIII) or formula (IX):
wherein:
In some aspects, the inositol phosphates of the present invention (e.g., Na6IP6 prepared according to the methods disclosed herein) or metabolites thereof can be detected and/or quantified using the methods disclosed in US9612250. See also, US8377909, US8778912, and US20070066574.
In some aspects, the inositol phosphates of the present invention (e.g., Na6IP6) are characterized for having a retention time of about 51.4 minutes for a phytic acid peak when an ion-exchange chromatography assay is performed.
The compounds disclosed herein (e.g., inositol phosphate salts prepared according to the methods disclosed herein) can be present in any form commonly used in pharmaceutical technology. Particular aspects include, but are not limited to, monovalent (e.g., sodium, potassium, ammonium) and divalent (e.g., magnesium) salts of inositol phosphate and the mixtures thereof. Other pharmaceutically acceptable salts are known to the person skilled in the art (Haynes D, et al., J. Pharmaceutical Sci. 2005; 94:2111-2120.
The present invention also provides pharmaceutical compositions to treat diseases and conditions wherein, e.g., chelation of divalent ions is desirable. The pharmaceutical compositions provided herein can also be used, e.g., in the treatment or prevention of pathological calcifications, the treatment of diseases or conditions associated with pathological calcification (e.g., ectopic calcifications) or the treatment of sequelae, complications or symptoms of diseases or conditions wherein such sequelae, complications or symptoms are calcifications (e.g., calcification related to dialysis).
In some aspects, the pharmaceutical composition comprises at least one inositol phosphate of the present invention (e.g., Na6IP6 prepared according to the methods disclosed herein). In some aspects, the pharmaceutical composition comprises an inositol phosphate of the present invention (e.g., Na6IP6 prepared according to the methods disclosed herein) together with one or more pharmaceutically acceptable excipients or carriers.
The term “excipient” as used herein refers to a substance which helps absorption of the elements of the pharmaceutical composition, stabilizes said elements, activates or helps preparation of the composition. Thus, examples of excipients used in parenteral formulations include, but are not limited to, antimicrobial agents (e.g., benzalkonium chloride, metacresol, thimerosal), co-solvents (e.g., ethanol), buffers and pH adjusting factors (e.g., carbonate, citrate, phosphate solutions).
As is the case for the excipient, the “pharmaceutically acceptable vehicle” is a substance used in the composition to dilute any of the components contained therein to a determined volume or weight. The pharmaceutically acceptable vehicle is an inert substance or a substance with an analogous action to any of the elements comprising the pharmaceutical composition of the present invention. The role of said vehicle is to allow the incorporation of other elements, allow better dosing and administration or to provide consistency and shape to the composition.
Pharmaceutical compositions can comprise from approximately 0.001% to approximately 95% active ingredient (e.g., Na6IP6 prepared according to the methods disclosed herein, alone or in a combination formulation, e.g., with one or more therapeutic agents disclosed in Table 1). In some aspects, e.g., the pharmaceutical compositions of the present invention can comprise from approximately 20% to approximately 90% active ingredient (e.g., Na6IP6 prepared according to the methods disclosed herein, alone or in a combination formulation, e.g., with one or more therapeutic agents disclosed in Table 1).
In some aspects, the concentration of inositol phosphate of the present invention (e.g., Na6IP6, K6IP6, (NH4)6IP6) in the aqueous pharmaceutical composition is between about 0.001 mg/mL and about 100 mg/mL. In one specific aspect, the concentration of inositol phosphate of the present invention (e.g., Na6IP6, K6IP6, (NH4)6IP6) in the aqueous pharmaceutical composition is between about 20 mg/mL and about 90 mg/mL.
In one specific aspect, the concentration of inositol phosphate of the present invention (e.g., Na6IP6, K6IP6, (NH4)6IP6) in the aqueous pharmaceutical composition is about 20 mg/mL. In another specific aspect, the concentration of inositol phosphate of the present invention (e.g., Na6IP6, K6IP6, (NH4)6IP6) in the aqueous pharmaceutical composition is about 30 mg/mL. In yet another specific aspect, the concentration of inositol phosphate of the present invention (e.g., Na6IP6, K6IP6, (NH4)6IP6) in the aqueous pharmaceutical composition is about 90 mg/mL.
In some aspects, the concentration of inositol phosphate of the present invention (e.g., Na6IP6, K6IP6, (NH4)6IP6) in the aqueous pharmaceutical composition is about 10 mg/mL, about 20 mg/mL, about 30 mg/mL, about 40 mg/mL, about 50 mg/mL, about 60 mg/mL, about 70 mg/mL, about 80 mg/mL, about 90 or about 100 mg/mL of inositol phosphate of the present invention.
In some aspects, the concentration of inositol phosphate of the present invention (e.g., Na6IP6, K6IP6, (NH4)6IP6) in the aqueous pharmaceutical composition is between about 20 mg/mL and about 100 mg/mL, between about 30 mg/mL and about 100 mg/mL, between about 40 mg/mL and about 100 mg/mL, between about 50 mg/mL and about 100 mg/mL, between about 60 mg/mL and about 100 mg/mL, between about 70 mg/mL and about 100 mg/mL, between about 80 mg/mL and about 100 mg/mL or between about 90 mg/mL and about 100 mg/mL of inositol phosphate of the present invention.
In some aspects, the concentration of inositol phosphate of the present invention (e.g., Na6IP6, K6IP6, (NH4)6IP6) in the aqueous pharmaceutical composition is between about 10 mg/mL and about 20 mg/mL, between about 10 mg/mL and about 30 mg/mL, between about 10 mg/mL and about 40 mg/mL, between about 10 mg/mL and about 50 mg/mL, between about 10 mg/mL and about 60 mg/mL, between about 10 mg/mL and about 70 mg/mL, between about 10 mg/mL and about 80 mg/mL or between about 10 mg/mL and about 90 mg/mL of inositol phosphate of the present invention.
In some aspects, the concentration of inositol phosphate of the present invention (e.g., Na6IP6, K6IP6, (NH4)6IP6) in the aqueous pharmaceutical composition is between about 10 mg/mL and about 20 mg/mL, between about 20 mg/mL and about 30 mg/mL, between about 30 mg/mL and about 40 mg/mL, between about 40 mg/mL and about 50 mg/mL, between about 50 mg/mL and about 60 mg/mL, between about 60 mg/mL and about 70 mg/mL, between about 70 mg/mL and about 80 mg/mL, between about 80 mg/mL and about 90 mg/mL or between about 90 mg/mL and about 100 mg/mL of inositol phosphate of the present invention.
In some aspects, the concentration of inositol phosphate of the present invention (e.g., Na6IP6, K6IP6, (NH4)6IP6) in the aqueous pharmaceutical composition is between about 10 mg/mL and about 30 mg/mL, between about 20 mg/mL and about 40 mg/mL, between about 30 mg/mL and about 50 mg/mL, between about 40 mg/mL and about 60 mg/mL, between about 50 mg/mL and about 70 mg/mL, between about 60 mg/mL and about 80 mg/mL, between about 70 mg/mL and about 90 mg/mL or between about 80 mg/mL and about 100 mg/mL of inositol phosphate of the present invention.
In some aspects, the concentration of inositol phosphate of the present invention (e.g., Na6IP6, K6IP6, (NH4)6IP6) in the aqueous pharmaceutical composition is between about 10 mg/mL and about 40 mg/mL, between about 20 mg/mL and about 50 mg/mL, between about 30 mg/mL and about 60 mg/mL, between about 40 mg/mL and about 70 mg/mL, between about 50 mg/mL and about 80 mg/mL, between about 60 mg/mL and about 90 mg/mL or between about 70 mg/mL and about 100 mg/mL of inositol phosphate of the present invention.
In some aspects, the concentration of inositol phosphate of the present invention (e.g., Na6IP6, K6IP6, (NH4)6IP6) in the aqueous pharmaceutical composition is between about 10 mg/mL and about 50 mg/mL, between about 20 mg/mL and about 60 mg/mL, between about 30 mg/mL and about 70 mg/mL, between about 40 mg/mL and about 80 mg/mL, between about 50 mg/mL and about 90 mg/mL or between about 60 mg/mL and about 100 mg/mL of inositol phosphate of the present invention.
In some aspects, the concentration of inositol phosphate of the present invention (e.g., Na6IP6, K6IP6, (NH4)6IP6) in the aqueous pharmaceutical composition is between about 10 mg/mL and about 60 mg/mL, between about 20 mg/mL and about 70 mg/mL, between about 30 mg/mL and about 80 mg/mL, between about 40 mg/mL and about 90 mg/mL or between about 50 mg/mL and about 100 mg/mL of inositol phosphate of the present invention.
In some aspects, the concentration of inositol phosphate of the present invention (e.g., Na6IP6, K6IP6, (NH4)6IP6) in the aqueous pharmaceutical composition is between about 10 mg/mL and about 55 mg/mL or between about 55 mg/mL and about 100 mg/mL of inositol phosphate of the present invention.
In some aspects, the pharmaceutical compositions of the present invention (e.g., containing Na6IP6) are characterized for having a retention time of about 51 minutes for a phytic acid peak when an ion-exchange chromatography assay is performed.
In some aspects, the present invention is directed to a pharmaceutical composition comprising: (a) about 10 mg/mL to about 100 mg/mL of Na6IP6, (b) about 0.001 mg/mL to 50 mg/mL of at least one tonicity agent, and (c) water. Said composition is characterized for being a stable solution (i.e., 25° C., 60% RH). In some aspects, the composition further comprises a pH buffer solution.
In some aspects, the Na6IP6 of the composition is characterized for being at least 70% (w/w) pure and comprising: (i) DL-Inositol 1,2,3,4,6-pentaphosphate ≤2.0% (w/w), (ii) DL-Inositol 1,2,3,5,6-pentaphosphate ≤ 4.0% (w/w), (iii) DL-Inositol 1,2,4,5,6-pentaphosphate ≤ 5.0% (w/w), and (iv) DL-Inositol 1,3,4,5,6-pentaphosphate ≤ 3.0% (w/w). In some aspects, the Na6IP6 of the composition is characterized for being at least 80% (w/w) pure and comprising: (i) DL-Inositol 1,2,3,4,6-pentaphosphate ≤ 1.4% (w/w), (ii) DL-Inositol 1,2,3,5,6-pentaphosphate ≤ 2.1% (w/w), (iii) DL-Inositol 1,2,4,5,6-pentaphosphate ≤ 2.6% (w/w), and (iv) DL-Inositol 1,3,4,5,6-pentaphosphate ≤ 0.52% (w/w). In some aspects, the Na6IP6 of the composition is obtained according to the methods disclosed herein.
In some aspects, the composition comprises about 20 mg/mL to about 90 mg/mL of Na6IP6. In some additional aspects, the composition comprises about 20 mg/mL, about 30 mg/mL or about 90 mg/mL of Na6IP6.
Examples of tonicity agents used in the pharmaceutical compositions of the invention include, but are not limited to dextrose, glycerin, and sodium chloride or a combination thereof. In some aspects, the agent is an aqueous solution about 0.01 mg/mL to about 10 mg/mL of sodium chloride. In some further aspects, the agent is an aqueous solution about 9 mg/mL of sodium chloride.
Examples of pH buffer solutions used in the pharmaceutical compositions of the invention include, but are not limited to citric acid, disodium phosphate dihydrate, sodium hydroxide, sodium dihydrogen phosphate dihydrate, and combinations thereof. In some aspects, the pH of the composition is of about 5.0 to about 7.0, at 25° C. as measured according to Ph. Eur. 2.2.3. In some aspects, the pH of the liquid composition is of about 5.5 to about 6.5, at 25° C. as measured according to Ph. Eur. 2.2.3. In some aspects, the pH buffer solution used in the composition is a sodium hydroxide solution having a pH of 5.0 to about 7.0, at 25° C. as measured according to Ph. Eur. 2.2.3. Formulations of a pharmaceutical composition suitable for parenteral administration comprise the active ingredient, e.g., an inositol phosphate of the present invention, combined with a pharmaceutically acceptable carrier, such as sterile water or sterile isotonic saline. Such formulations can be prepared, packaged or sold in a form suitable for bolus administration or for continuous administration. Injectable formulations can be prepared, packaged or sold in unit dosage form, such as in ampules or in multi-dose containers containing a preservative. Formulations for parenteral administration include, but are not limited to, suspensions, solutions, emulsions in oily or aqueous vehicles, pastes, and implantable sustained-release or biodegradable formulations. Such formulations can further comprise one or more additional ingredients including, but not limited to, suspending, stabilizing or dispersing agents.
In some aspects, in a formulation for parenteral administration, the active ingredient, (e.g., Na6IP6 prepared according to the methods disclosed herein), is provided in dry (i.e., powder or granular) form for reconstitution with a suitable vehicle (e.g., water for injection) prior to parenteral administration of the reconstituted composition.
The pharmaceutical compositions can be prepared, packaged or sold in the form of a sterile injectable aqueous suspension or solution. This suspension or solution can be formulated according to the known art, and may comprise, in addition to the active ingredient (e.g., Na6IP6 prepared according to the methods disclosed herein, alone or in a combination formulation, e.g., with one or more therapeutic agents disclosed in Table 1), additional ingredients such as the dispersing agents, wetting agents or suspending agents described herein. Such sterile injectable formulations can be prepared using a non-toxic parenterally-acceptable diluent or solvent, such as water. Other acceptable diluents and solvents include, but are not limited to, Ringer’s solution and isotonic sodium chloride solution.
Other parentally-administrable formulations which are useful include those which comprise the active ingredient in microcrystalline form, in a liposomal preparation or as a component of a biodegradable polymer system. Compositions for sustained release or implantation can comprise pharmaceutically acceptable polymeric or hydrophobic materials such as an emulsion, an ion exchange resin, a sparingly soluble polymer or a sparingly soluble salt.
Controlled- or sustained-release formulations of a pharmaceutical composition of the present invention (e.g., pharmaceutical composition comprising Na6IP6 prepared according to the methods disclosed herein, alone or in a combination formulation, e.g., with one or more therapeutic agents disclosed in Table 1) can be made using conventional technology. In some cases, the dosage forms to be used can be provided as slow or controlled-release of one or more active ingredients therein using, for example, hydropropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes or microspheres or a combination thereof to provide the desired release profile in varying proportions.
Suitable controlled-release formulations known to those skilled in the art, including those described herein, can be readily selected for use with the pharmaceutical compositions of the invention. Thus, single unit dosage forms suitable for parenteral or topical administration, such as injectable solutions, gels, creams, and ointments, which are adapted for controlled-release are encompassed by the present invention.
Most controlled-release pharmaceutical products have a common goal of improving therapy over that achieved by their non-controlled counterparts. Ideally, the use of an optimally designed controlled-release preparation in medical treatment is characterized by a minimum of therapeutic agent being employed to cure or control the condition in a minimum amount of time. Advantages of controlled-release formulations include extended activity of the therapeutic agent, reduced dosage frequency, and increased patient compliance. In addition, controlled-release formulations can be used to affect the time of onset of action or other characteristics, such as blood level of the therapeutic agent, and thus can affect the occurrence of side effects.
Most controlled-release formulations are designed to initially release an amount of therapeutic agent that promptly produces the desired therapeutic effect, and gradually and continually release of other amounts of therapeutic agent to maintain this level of therapeutic effect over an extended period of time. In order to maintain this constant level of therapeutic agent in the body, the therapeutic agent must be released from the dosage form at a rate that will replace the amount of therapeutic agent being metabolized and excreted from the body.
Controlled-release of an active ingredient can be stimulated by various inducers, for example pH, temperature, enzymes, water or other physiological conditions or compounds. The term “controlled-release component” in the context of the present invention is defined herein as a compound or compounds, including, but not limited to, polymers, polymer matrices, gels, permeable membranes, liposomes or microspheres or a combination thereof that facilitates the controlled-release of the active ingredient.
In certain aspects, the formulations of the present invention can be, but are not limited to, short-term, rapid-offset, as well as controlled, for example, sustained release, delayed release and pulsatile release formulations.
The term sustained release is used in its conventional sense to refer to a therapeutic agent formulation (e.g., pharmaceutical composition comprising Na6IP6 prepared according to the methods disclosed herein, alone or in a combination formulation, e.g., with one or more therapeutic agents disclosed in Table 1) that provides for gradual release of a therapeutic agent over an extended period of time, and that can, although not necessarily, result in substantially constant blood levels of a therapeutic agent over an extended time period. The period of time can be as long as a month or more and should be a release which is longer that the same amount of agent administered in bolus form.
For sustained release, the compounds may be formulated with a suitable polymer or hydrophobic material which provides sustained release properties to the compounds. As such, the compounds for use the method of the present invention can be administered in the form of microparticles, for example, by injection or in the form of wafers or discs by implantation. In certain aspects, the compounds of the invention are administered to a patient, alone or in combination with another pharmaceutical agent, using a sustained release formulation.
The term delayed release is used herein in its conventional sense to refer to a therapeutic agent formulation that provides for an initial release of the therapeutic agent after some delay following therapeutic agent administration. The delay may be from about 10 minutes up to about 12 hours. The term pulsatile release is used herein in its conventional sense to refer to a therapeutic agent formulation that provides release of the therapeutic agent in such a way as to produce pulsed plasma profiles of the therapeutic agent after administration. The term immediate release is used in its conventional sense to refer to a therapeutic agent formulation that provides for release of the therapeutic agent immediately after administration.
As used herein, short-term refers to any period of time up to and including about 8 hours, about 7 hours, about 6 hours, about 5 hours, about 4 hours, about 3 hours, about 2 hours, about 1 hour, about 40 minutes, about 20 minutes or about 10 minutes and any or all whole or partial increments thereof after therapeutic agent administration.
As used herein, rapid-offset refers to any period of time up to and including about 8 hours, about 7 hours, about 6 hours, about 5 hours, about 4 hours, about 3 hours, about 2 hours, about 1 hour, about 40 minutes, about 20 minutes or about 10 minutes, and any and all whole or partial increments thereof after therapeutic agent administration.
Additional formulations and dosage forms of the compositions of the present invention include dosage forms as described in US6340475, US6488962, US6451808, US5972389, US5582837, and US5007790. See also, US0030147952, US20030104062, US20030104053, US20030044466, US20030039688, and US20020051820; WO200335041, WO200335040, WO200335029, WO200335177, WO2003035039, WO2002096404, WO2002032416, WO2001097783, WO2001056544, WO2001032217, WO1998055107, WO1998011879, WO1997047285, WO1993018755, and WO1990011757.
Medicaments comprising inositol phosphates prepared according to the methods of the invention can be manufactured by methods known in the art, especially by conventional mixing, coating, granulating, dissolving or lyophilizing.
The present invention also provides a compound, combinations of compounds or pharmaceutical formulations according to any of the above aspects of the invention, in the broadest definition given or as specified in any of the aspects presented above, for use as a medicament.
The present invention also provides a compound, combination of compounds or pharmaceutical formulation according to any of the above aspects of the invention, in the broadest definition given or as specified in any of the aspects presented above, for use in the treatment and/or prevention of a disease or condition disclosed herein (e.g., pathological calcification).
The present invention also provides a compound or combination of compounds or pharmaceutical formulation according to any of the above aspects of the invention, in the broadest definition given or as specified in any of the aspects presented above, for the manufacture of a medicament for the prevention and/or treatment of a disease or condition disclosed herein.
In some aspects, the compositions disclosed herein can be used as nutraceuticals or as components of functional foods.
The present invention also provides combination treatments comprising the administration of an inositol phosphate of the invention (e.g., Na6IP6 prepared according to the methods disclosed herein) and at least one additional therapeutic agent. Also provided are combined compositions comprising an inositol phosphate of the invention (e.g., Na6IP6 prepared according to the methods disclosed herein) and at least one additional therapeutic agent. Thus, a further aspect of the present invention relates to a composition comprising at least one inositol phosphate of the invention (e.g., Na6IP6 prepared according to the methods disclosed herein) and another therapeutic agent.
The “term “combination therapy” as used herein refers interchangeably to both combination treatments according to the methods and dosages disclosed herein, and to combined compositions. As used herein the term “combined composition” does not imply the components of the combined composition need to be present together. Consequently, the expression implies that the combination is not necessarily a true combination in light of the physical separation of the components thereof. For example, the components in a combined composition can be applied separately, sequentially or their application can overlap.
In some aspects, the additional therapeutic agent is selected, e.g., from the compositions presented in Table 1. In some aspects, a combination therapy can comprise an inositol phosphate of the invention (e.g., Na6IP6 prepared according to the methods disclosed herein) and a therapeutic agent from Table 1. In other aspects, a combination therapy can comprise an inositol phosphate of the invention (e.g., Na6IP6 prepared according to the methods disclosed herein) and more than one therapeutic agent from Table 1. When more than one therapeutic agent from Table 1 is present in a combination therapy, the therapeutic agents from Table 1 can belong to the same indication or to different indications. For example, a combination composition can comprise a treatment (e.g., OPG), a wound healing compound, and a pain management compound.
Several of the compounds described as additional therapeutic agents change the thermodynamics of the crystallization process by modifying the concentration of the ions present in the structure of the calcium-containing crystal that results in an ectopic calcification. This sub-group includes calcimimetics, phosphate chelators, thiosulfate or vitamin D.
Calcimimetics allow the calcium and phosphate concentration to be controlled by regulating blood PTH levels. Said compounds include, e.g., cinacalcet, NPS R-467, NPS R-568, and KAI-4169.
In some aspects, the combination composition comprises a vitamin selected from vitamin B, vitamin D, vitamin K or a combination thereof. Although with a different mechanism of action, vitamin D has a similar effect. The vitamin D is preferably selected from the group consisting of calciferol, ergocalciferol (Vitamin D2), cholecalciferol (Vitamin D3), doxercalciferol, paricalcitol alfarol, alpha-calcidol calcidiol, calcitriol, derivatives or pharmaceutically acceptable salts thereof or any combinations thereof.
Phosphate binders act by sequestering phosphate thereby reducing the systemic concentration thereof in blood. The phosphate binder can contain a metal or be metal-free. Metal-free chelators include, e.g., sevelamer. Metal-containing chelators include, e.g., various calcium, iron, lanthanum, aluminum, and magnesium salts. Thiosulfate is a chelator that reduces the free calcium concentration in blood.
Other compounds (e.g., pyrophosphate, citrate, bisphosphonates, antihypertensives, anticholesteremic agents, vitamin B or vitamin K) that can be used in combination therapies act against the altered calcium and phosphate metabolism kinetically by attempting to stop the crystallization process or altering bone metabolism by increasing the amount of repressor factors (pyrophosphate, citrate, vitamin B, vitamin K, bisphosphonates) or by reducing the quantity of promoter factors (necrotic remains or organic matter in the case of antihypertensives or lipid deposits in the case of anticholesteremic agents).
In some aspects, the bisphosphonate can contain nitrogen or be nitrogen-free. In some aspects, the bisphosphonate can be selected from the group consisting of etidronate, alendronate, risedronate, zoledronate, tiludronate, pamidronate, monidronate, neridronate, pamidronate, olpadronate, clodronate, ibandronate, and combinations thereof.
In some aspects, the combination therapy can comprise an anticholesteremic agent selected from the group consisting of statins, fibrates, niacin, acid sequestrants, ezetimibe, lomitapide, phytosterols orlistat, and combinations thereof.
Compounds that can be also used for the treatment of ectopic calcifications also include those disclosed in US9629872, WO2017131127, US5362886, US4024175, and US3159581.
The present invention also provides articles of manufacture and kits comprising an inositol phosphate of the present invention (e.g., Na6IP6 prepared according to the methods disclosed herein). Such articles of manufacture and kits can comprise a container (e.g., a box) comprising one or more vials containing a formulation comprising one or more of the salts of inositol hexaphosphate (e.g., Na6IP6) disclosed herein and/or solvents for their administration according to the methods disclosed herein.
A kit or article of manufacture provided according to this invention can also comprise brochures or instructions describing the process of administration and dosages disclosed herein. In some aspects, kit or article of manufacture can comprise multiple vials, each one of them containing a single dose. In other aspects, kits or article of manufacture can comprise one or more vials, each one of them comprising more than one dose.
In some aspects, the article of manufacture is a bag or syringe containing a solution prepared by dissolving a salt of inositol hexaphosphate (e.g., Na6IP6) disclosed herein. In other aspects, the article of manufacture is a bottle (e.g., a glass bottle or a plastic bottle) containing a solution prepared by dissolving a salt of inositol hexaphosphate (e.g., Na6IP6) disclosed herein.
In some aspects, the article of manufacture is a bag containing a salt of inositol hexaphosphate (e.g., Na6IP6) disclosed herein in powder form for reconstitution in an appropriate solvent. In other aspects, the article of manufacture is a bottle (e.g., a glass bottle or a plastic bottle) containing a salt of inositol hexaphosphate (e.g., Na6IP6) disclosed herein in powder form for reconstitution in an appropriate solvent.
The kits and articles of manufacture can include instructions for carrying out one or more administrations of a salt of inositol hexaphosphate (e.g., Na6IP6) disclosed herein prepared according to the methods disclosed herein.
Instructions included in the kits and articles of manufacture can be affixed to packaging material or can be included as a package insert. While the instructions are typically written or printed, materials are not limited to such. Any medium capable of storing such instructions and communicating them to an end user is contemplated. Such media include, but are not limited to, electronic storage media (e.g., magnetic discs, tapes, cartridges, chips), optical media (e.g., CD ROM), and the like. As used herein, the term “instructions” can include the address of an internet site that provides the instructions.
The present invention also provides methods for treating or preventing ectopic calcification or its consequences in a subject in need thereof which comprises administering a compound prepared according to the process of any one of claims, a soluble IP salt prepared according to the methods disclosed herein (e.g., Na6IP6), a pharmaceutical composition disclosed herein, a combination treatment disclosed herein or a kit disclosed herein to the subject. Alternatively, the present invention provides a compound prepared according to the process of any one of claims, a soluble IP salt prepared according to the methods disclosed herein (e.g., Na6IP6), a pharmaceutical composition disclosed herein, a combination treatment disclosed herein or a kit disclosed for use in the treatment or prevention of ectopic calcification or its consequences in a subject in need thereof. Alternatively, the present invention provides the use of a compound prepared according to the process of any one of claims, a soluble IP salt prepared according to the methods disclosed herein (e.g., Na6IP6), a pharmaceutical composition disclosed herein, a combination treatment disclosed herein or a kit disclosed herein in the preparation of a medicament for treating or preventing ectopic calcification or its consequences in a subject in need thereof. In some aspects, the subject is undergoing hemodialysis. In some aspects, the subject has end-stage renal disease. In some aspects, the soluble IP salt, pharmaceutical composition, combination treatment or kit disclosed herein comprises a salt of inositol hexaphosphate (e.g., Na6IP6) prepared according to the methods disclosed herein.
In some aspects, the salt of inositol hexaphosphate (e.g., Na6IP6) disclosed herein can be used to treat and/or present pathological calcifications, e.g., ectopic calcification such as calciphylaxis, and/or the consequences thereof in a subject. In some aspects, the salt of inositol hexaphosphate (e.g., Na6IP6) disclosed herein can be administered in at least one dose in a dosage of about 5 mg to 10 mg per kg per administration to the subject (e.g., a dosage of about 6 mg/kg to about 9 mg/kg, such as 6 mg/kg or 9 mg/kg), at least one per week (e.g., once, twice or three times per week), for a variable period of time (e.g., from about 1 week to about 12 weeks, about 24 weeks or about 52 weeks) or chronically wherein the administration of the dosage effectively treats and/or prevents the pathological calcification, e.g., ectopic calcification such as calciphylaxis, and/or the consequences thereof in the subject.
In some aspects, the inositol phosphates of the present invention can be administered by any appropriate method such as parenteral (e.g., subcutaneous, subcutaneous depot, intraperitoneal, intramuscular, intradermal, intrathecal, epidural, spinal, intravascular, intravenous, intravenous infusion), topical, (e.g., intranasal, inhalation, intravaginal, transdermal), enteral (e.g., oral, sublingual, rectal) or others known to a person skilled in the art. In some aspects, the inositol phosphates of the present invention can be administered by a method that provokes a non-bolus type release or effect in the subject.
In a particular aspect of the present invention, a myo-inositol hexaphosphate (or a formulation comprising a hexasodium salt of myo-inositol hexaphosphate such as SNF472) prepared according to the methods disclosed herein is administered intravenously via intravenous infusion. In another particular aspect of the present invention, a myo-inositol hexaphosphate prepared according to the methods disclosed herein (e.g., Na6IP6) is administered subcutaneously. In another particular aspect of the present invention, a myo-inositol hexaphosphate prepared according to the methods disclosed herein (e.g., Na6IP6) is administered topically.
In some aspect, when an inositol phosphate of the present invention (e.g., Na6IP6) is administered to a patient undergoing dialysis, such administration (e.g., intravenous administration via infusion) can occur during a dialysis treatment.
In some aspects, the administration of the dosage of inositol phosphate of the present invention (e.g., Na6IP6) to the subject inhibits the formation and/or growth of hydroxyapatite crystals, e.g., on teeth, and their deposition in ectopic calcifications, e.g., in calciphylaxis calcification. In some aspects, the ectopic calcification is, e.g., a calciphylaxis calcification, a metastatic calcification, a dystrophic calcification, an iatrogenic calcification, an idiopathic calcification or a subcutaneous ectopic ossification.
In some aspects, the consequence of the ectopic calcification is, e.g., (i) a functional complication, (ii) pain, (iii) a trophic complication, (iv) an infection or (v) a combination thereof. In some aspects, the function complication is, e.g., a limitation of range of motion and/or joint function. In some aspects, the trophic complication is, e.g., ischemia and/or a lesion. In some aspects, the lesion is, e.g., necrosis of the cutaneous and/or subcutaneous tissues.
The methods, compositions, pharmaceutical compositions and formulations, articles of manufacture and kits comprising inositol phosphates of the present invention disclosed herein, can be used to treat and/prevent ectopic calcifications, and in particular cutaneous or subcutaneous calcification such as calciphylaxis calcifications, and/or the consequences thereof in a subject in need thereof.
Cutaneous and subcutaneous calcifications (in general referred to as ectopic calcifications) are related to the pathological crystallization of calcium and arise as complications in numerous diseases. Ectopic calcifications can be classified into dystrophic, metastatic, idiopathic or iatrogenic calcifications or into calciphylaxis.
Dystrophic calcifications result from local tissue abnormalities and grow in spite of normal plasma calcium and phosphorus levels. The main diseases that can develop due to these calcifications are: connective tissue diseases (e.g., scleroderma, CREST syndrome, juvenile dermatomyositis, lupus), cutaneous and subcutaneous infections (e.g., panniculitis), skin tumors (in particular pilomatricoma), certain congenital diseases (e.g., Elher-Danlos disease, Werner’s syndrome, pseudo xanthoma elasticum (PXE)).
Metastatic calcifications are the result of a disorder of calcium and phosphate metabolism (hypercalcemia and/or hyperphosphatemia). All diseases that cause these disorders can therefore contribute to the development of calcifications.
Idiopathic calcifications occur without tissue lesions or disorders of calcium and phosphate metabolism. The main known diseases in this group are tumoral calcinosis, scrotal calcifications as well as sub-epidermal calcified nodules.
Iatrogenic calcifications can occur following the injection of calcium or para-aminosalycylic acid. They have also been described following the use of calcium chloride saturated electrodes.
Soft tissue calcifications (e.g., cutaneous or subcutaneous calcifications) can be associated with a disease or pathological condition selected from the group consisting of primary hyperparathyroidism, vitamin D intoxication, milk drinker’s syndrome, hypercalcemia, secondary hyperparathyroidism, renal failure, hyperphosphatemia, in particular genetic hyperphosphatemia, scleroderma, dermatomyositis, in particular the juvenile form, mixed connective tissue diseases, lupus, CREST syndrome, Elhers-Danlos syndrome, PXE, Werner’s syndrome, late cutaneous porphyria, pseudo hypoparathyroidism, pseudo pseudo-hypoparathyroidism, (primary or secondary) venous or arterial insufficiency, diabetes, scrotal calcinosis, ossifying myositis, post-traumatic ectopic ossifications and any other disease or pathological condition caused by calcium crystal deposit(s), in particular of hydroxyapatite or calcium pyrophosphate, e.g., calciphylaxis.
An important concept is that various disorders, including those listed in the previous paragraphs, can be treated by preventing, reducing, slowing or stopping the progression of calcification in the presence of uremia. The disease related to calcium disorders or the calcification induced by said disease, can already be present when administration commences, in order to reduce or stop progression of the disease or cannot yet be present, in order to prevent the appearance or onset of the disease.
Calciphylaxis corresponds to the calcification of small sized blood vessels and of the sub-cutaneous adipose tissue. Calciphylaxis can be treated concurrently with at least the following diseases: hypercalcemia, hyperphosphatemia, secondary and tertiary hyperparathyroidism, hypoparathyroidism or any combination thereof.
Further conditions that can benefit from a treatment with the inositol phosphates of the invention (e.g., Na6IP6 prepared according to the methods disclosed herein), peripheral arterial disease, critical limb ischemia, general arterial calcification of infancy, aortic valve stenosis, atherosclerosis, pseudo gout, primary hyperoxaluria, and pseudoxanthoma elasticum.
In the context of the present invention, “peripheral arterial disease” refers to a narrowing of the peripheral arteries to the legs (most commonly), stomach, arms, and head. Symptoms include intermittent claudication (leg pain when walking which resolves with rest), skin ulcers, bluish skin, cold skin or poor nail and hair growth.
In the context of the present invention, “critical limb ischemia” refers to a severe obstruction of the arteries which markedly reduces blood flow to the extremities and progresses to the point of severe pain and even skin ulcers, sores or gangrene. Critical limb ischemia is a very severe condition of peripheral artery disease.
In the context of the present invention, “pseudogout”, also known as “Calcium pyrophosphate dihydrate (CPPD) crystal deposition disease” or “pyrophosphate arthropathy” refers to a rheumatologic disorder believed to be caused by calcium pyrophosphate crystal accumulation in connective tissues, particularly joints such as the knee joint.
In the context of the present invention, the term “general arterial calcification of infancy” (GACI) relates to a disorder affecting the circulatory system that becomes apparent before birth or within the first few months of life, and which is characterized by abnormal calcification of the arteries and thickening of the arterial walls. These changes lead to stenosis and stiffness of the arteries, resulting in heart failure in some affected individuals, with signs and symptoms including difficulty breathing, edema, cyanosis, hypertension, and cardiomegaly.
In some aspects, the administration of the dosage of inositol phosphate of the present invention (e.g., Na6IP6), can be used to treat a bacterial infection, e.g., a Clostridium difficile infection. In some aspects, the inositol phosphates of the present invention (e.g., Na6IP6) can be administered as nutraceuticals or functional foods.
In some aspects, an inositol phosphate of the present invention (e.g., Na6IP6 prepared according to the methods disclosed herein) can be used, e.g., as an antioxidant or as a medicament to reduce or inhibit atherosclerotic plaque formation, reduce inflammation, lower cholesterol and/or triglycerides, reduce arterial obstruction, reduce arterial inflammation, reduce heart disease, reduce or inhibit platelet aggregation or decrease insulin resistance in type II diabetes affected patients.
The following examples present improved synthesis processes for the synthesis of the active substance in SNF472 (hexasodium phytate), as well as intermediates (e.g., Na12IP6) and variants thereof (e.g., K12IP6 or K6IP6). The processes provided below are exceedingly efficient and result in a final product with a high degree of purity.
Screening of solvent combinations for recrystallization: The first experiments focused on Na12IP6 crystallization methods with precipitation from water by addition of an antisolvent. The advantage of these methods was that no heating above room temperature was required. No solvent combination or precipitation mode recrystallized phytate. In all experiments oiling/formation of sticky material was observed. Furthermore, analytical data showed no significant purification effect. See Table 4.
Recrystallization from water: After the first unsuccessful recrystallization attempts with precipitation by addition of an antisolvent, an alternative method was required. Direct recrystallization from water was investigated. Initial stability tests in water at 50° C. for 3 days showed no significant decomposition by 31P-NMR. A significant purification effect was achieved with this recrystallization procedure. See Table 5.
Crystallization temperature: The experimental results summarized in Table 6 indicated that the crystallization temperature had a strong influence on the isolated yield. Furthermore, more impurities were precipitated at lower temperature. A significant improvement regarding impurity profile and yield was reached at 15-21° C.
Crystallization time: It has been observed that the crystallization of the product was quite slow. Longer stirring times lead to more yield. Best crystallization time was at least 27 hours since increased impurities levels were observed after longer periods. See Table 7.
Washing procedure: It was observed that the material isolated after recrystallization in water tended to clump during the drying process. Washing with ethanol before drying led to an improvement and isolation of a homogeneous, fine crystalline powder.
Drying conditions: Elevated drying temperature of 40° C. had a significant effect on drying times without impacting the impurity profile of the isolated product. Therefore, drying at 40° C. was selected. See Table 8.
Based on the experience of Example 1, a process for recrystallizing Na12IP6 was devised comprising the recrystallization of the product from water and involving a centrifugation step. Ethanol was used to rinse the product before the drying step. The recrystallization was performed in a 1000L reactor, while a centrifuge was used for isolation. The product was then dried on a tray dryer.
Manufacture process: The original phytate material was obtained from rice (Oryza sativa) hulls. A 400 L reactor was flushed with nitrogen and filled with 61.0 kg EP/USP water. A 200 L pressure filter was charged with 20.0 kg CELITE® 545, and the water was emptied from the 400 L reactor into a 1000 L reactor via the pressure filter with BECOPAD® P170 depth filter medium until the CELITE® in the pressure filter began to get dry on the surface. The 400 L reactor was charged with a total of 181.8 kg water and 96.6 kg of the Na12IP6 starting material at 15.5-21.4° C. while stirring at 96 rpm. The white suspension was then heated over one hour until 50° C. have been reached and a light-yellow solution was obtained.
The warm solution was filtered over the heated (45° C.) pressure filter into the pre-heated 1000 L reactor. The filter residue was washed with 12.5 kg of pre-heated water. Afterwards, the solution was cooled down within 1 h 50 min from 48.5° C. to 20° C. 97 g of previously recrystallized Na12IP6 batch were added as seeding crystals, and the mixture was stirred during 62 h 15 min between 20° C. and 18.5° C. to form a white suspension. Alternatively, a non-seeded solution may be stirred for a longer time (e.g., around 75 h) to obtain similar results. See Table 5.
In a next step, the suspension was centrifuged washed one time with 24.5 kg water and two times with a total of 38.2 L ethanol. After unloading of the centrifuge 75.0 kg of wet material have been obtained. The product was then transferred to a tray dryer where it was dried for 14 h 10 min at 19.5-32° C. and 200-20 mbar (condensation phase) and later for 148 h 20 min at 32-36° C. and 2 mbar (final drying phase).
A loss on drying as in-process control was performed and showed a result of 5.39% (set value: <= 10.0%). The tray dryer oven was unloaded into a 120L high-density polyethylene (HDPE) drum with a double low-density polyethylene (LDPE) in-liner. The product was homogenized on a gym wheel mixer for 20 min at a speed level of 3.
47.4 kg of recrystallized Na12IP6 were obtained, representing a yield of 49.2%. QC samples we retained and also material to be used as seeding crystals for future batches.
An alternative to the Example 2 process for recrystallizing Na12IP6 was devised comprising a filtration step instead of a centrifugation step.
Manufacture process: A 400 L reactor was flushed with nitrogen and filled with 60 kg EP/USP water. A 200 L pressure filter was charged with 20 kg of CELITE® 545, and the water was emptied from the 400 L reactor in a 630 L reactor via the pressure filter. The 400 L reactor was charged with a total of 186.5 kg water and 100 kg of Na12IP6 starting material at 18.8-20.6° C. while stirring at 100 rpm. The white suspension was then heated over two hours until a temperature of 48.2° C. was reached and a light-yellow clear solution was obtained. The warm solution was filtered over the heated (50° C.) pressure filter into the heated 630 L reactor.
The filtered residue was washed with 13.5 kg of pre-heated water. Then, the solution was cooled down within 2 h 40 min from 46.8° C. to 20.2° C. 100 g of previously recrystallized Na12IP6 were added as seeding crystals. The mixture was stirred for approximately 60 h between 20.0° C. and 19.1° C. until a white suspension was formed. Alternatively, a non-seeded solution may be stirred for a longer time (e.g., around 75 h) to obtain similar results. See Table 5.
Afterwards, the suspension was filtered over a 200 L agitated filter dryer and was washed once with 25 kg of water. The suspension was then washed twice with 19.7 kg and 19.6 kg of an ethanol solution. The filter dryer was heated, and vacuum was applied at 3 mbar. The drying process was maintained at a temperature below 36° C. until a loss on drying ≤10% was reached or approximately 10 days.
The product was then unloaded and filled in one 120 L HDPE drum with a double LDPE in-liner.
51.6 kg of recrystallized Na12IP6 were obtained, representing a yield of 51.6% w/w over the starting material.
K12IP6 is used as starting material for recrystallization as an intermediate step in the production of K6IP6. A first reactor is flushed with nitrogen and filled with water. A pressure filter is charged, e.g., with CELITE® 545, and the water is emptied from the first reactor into a second reactor via the pressure filter. The first reactor is charged with water and 50 kg of K12IP6 starting material at 15-25° C. while stirring at 100 rpm. The suspension is then heated over two hours until a temperature of approx. 40-50° C. is reached and a clear solution is obtained. The warm solution is filtered over the heated (e.g., at 50° C.) pressure filter into the heated second reactor.
The filter residue is washed with pre-heated water. Then, the solution is cooled down within 2-3 h from 40-50° C. to 15-25° C. A seed amount of previously recrystallized K12IP6 is added as seeding crystals. The mixture is stirred for approximately 50-75 h at approximately 20.0° C. until a suspension was formed.
Afterwards, the suspension is filtered over an agitated filter dryer and is washed once with water. The suspension is then washed twice with a 1:1 water:ethanol solution. The filter dryer is heated, and vacuum is applied at 3 mbar. The drying process is maintained at a temperature below 40° C. until a loss on drying ≤10% is reached. The product is then unloaded and filled in a HDPE drum with a double LDPE in-liner.
24.5 kg of recrystallized K12IP6 were obtained, representing a yield of 49.0% w/w over the starting material.
In some aspects of this method, the suspension can be purified by centrifugation instead of filtration, as described in Example 2 for the recrystallization of Na12IP6.
The manufacture of Na6IP6 using non-recrystallized Na12IP6 as starting material comprised the following steps (Process 1):
1. 3.36 L (4.8 volumes) of purified water were charged to a reactor with jacket temp 24° C. ±3° C. Stirring was started at medium-high speed and 0.7 kg dodecasodium phytate were added lowly over 30 min. The reaction was slightly exothermic; therefore, speed of addition was controlled to keep temperature below 30° C. The mixture was stirred for further 60 minutes to ensure full dissolution was achieved.
2. The solution was filtered and transferred from the reactor to drum(s).
3. 1 CV (column volume) of purified water was flowed through an activated AMBERLITE® ion-exchange column. The flowing of the phytate solution commenced immediately.
4. Fraction collection commenced once loading of sample started and pH measured throughout elution and subsequent wash. Fraction size was approx. ⅛ of the CV (approximately 10 L) but new containers were taken at specific pHs even if current fraction was not full.
5. Each container was changed once pH <1.5, again when pH <1.25 and finally when pH <1.0
6. The solution was chased with 1 CV purified water and fraction collection restarted in new container until pH >1.0, changed again when pH > 1.25 and again >1.5.
7. pH probe was rinsed well in purified water and retaken pH of fractions. 2ml of appropriate fractions (pH >2) from each container were submitted for UV testing.
8. The previous steps were repeated, 0.7 kg of dodecasodium phytate at a time, until the entire batch had been processed.
9. Three volumes of ethanol were charged to reactor and chilled to 5° C.
10. Distillation was carried at 40° C. temperature. Maximum temperature did not exceed 45° C. until target distillate volume had been removed or maximum distillation time of 8 hours had been reached. Syrup should be colorless to very pale yellow.
11. The reactor was rinsed with water and the previous step was repeated until the entire batch had been processed.
12. Total weight of phytic acid added to the reactor and total volume ethanol used to discharge syrup were calculated and ethanol was added until a total of 10 volumes of ethanol had been charged to the reactor.
13. The reactor jacket was set to 15° C. and the solution was stirred until internal temperature reached 15° C.
14. Jacket temperature was reset to 10° C. and the solution was stirred at 130 RPM. Sodium methoxide was added portion wise at a rate of 2.5% per minute. pH was monitored throughout the addition of each portion. Addition of sodium methoxide was stopped if pH >5.0 at any point. Solution was allowed to equilibrate, and pH measured after 5 minutes. After addition of 85% of the total charge of sodium methoxide, equilibration time was increased to 15 minutes. If temperature increased above 20° C., addition of sodium methoxide was stopped until temperature decreased to 15 ± 2° C.
15. Slurry was chilled to 5° C. with a jacket temperature of 0° C. Once internal temperature reached 5° C., jacket temperature was raised to 5° C. and stirred for 30 minutes. A 10 ml sample was taken, and if pH was between 4.3 and 5.3 the process continued. Otherwise, sodium methoxide was added in 1% increments until pH was within the pH 4.3-5.3 range.
16. Slurry was stirred at 5° C. for further 1.5 hours, then internal temperature was increased to 10° C., maximum jacket temperature was 15° C. 10 volumes of acetone were added. The mixture was stirred for 60 minutes and then jacket temperature was decreased to 0° C. The mixture was stirred until internal temperature reached 5° C. Jacket temperature was raised to 5° C. and mixture was stirred for 30 minutes.
17. Solid was isolated using centrifuge under nitrogen until a dry solid was obtained. Each cake was washed with 2 volumes of acetone.
18. Reactor was charged with 10 volumes of acetone. All portions of cake from previous step charged and slurry was stirred at 15° C. for 1.5 hours.
19. Jacket temperature was set to 0° C. and solution was chilled to 5° C. Once slurry reaches 5° C., jacket temperature was raised to 5° C. and slurry was stirred for 30 minutes.
20. Solid was isolated using centrifuge under nitrogen until a dry solid was obtained. Each cake was washed with 2 volumes acetone with respect to phytic acid weight.
21. Reactor was charged with 10 volumes of acetone. All portions of cake from the previous step were recharged and slurry was stirred at 15° C. for 1.5 hours.
22. Jacket temperature was set to 0° C. Solution was chilled solution to 5° C. Once slurry reached 5° C. jacket temperature was raised to 5° C. and stirred for 30 minutes.
23. Solid was isolated using centrifuge under nitrogen until a dry solid was obtained. Each cake was washed with 2 volumes of acetone with respect to phytic acid weight.
24. All material from previous steps was loaded into vacuum oven and dried without heat and with small nitrogen bleed. Cake was broken up and stirred every 6 hours. Drying continued until result returned or maximum 48 hours drying time reached. Trays were discharged from oven and stored at -20° C. under desiccant.
25. Material was discharged into liners, doubled with desiccant sachets between liners and deposited in curtec drum.
As a result of this process Na6IP6 salt 73.4% w/w pure containing the following impurities was obtained:
A comparison of the products obtained in Processes 1, 2, and 3 is presented in Table 9, See below.
The manufacture of Na6IP6 using non-recrystallized Na12IP6 as starting material comprised the following steps in Process 2.
1. A column was flushed with 3 CV of purified water and emptied.
2. Resin equivalent to approximately 75% of column volume was added.
3. Purified water was added to top of the resin bed, center tube was replaced, and the remaining resin was added.
4. Purified water was added to just above top resin bed, the top of the column was screwed on, and attached to the diaphragm pump (in reverse) ensuring it was leak free.
5. At least 5 CV purified water were flowed through the resin in reverse flow (bottom to top).
6. Lines were switched so flow was top to bottom and flow was at least 5 CV.
7. 5 CV of 1 M HCl were flowed through the column. If pH at end volume was <0.4 process continued to step 9. If pH was >0.4, process continued to step 8.
8. 1 CV of 1 M HCl was flowed through column 1. If pH at end volume <0.4 process continued to step 9. If pH >0.4, step 8 was repeated until pH <0.4.
9. 4 CV of 1 M purified water were flowed through vessel. pH at end volume was >3.25.
10. 1 CV of 1 M purified water was flowed through column 1 at. If pH at end volume was >3.25 process proceeded to step 11. If pH <3.25, step 10 was repeated until pH >3.25.
11. IPC1: Purity by IC of final purified water wash. Target: RRT 0.69 area ≤ 0.04µS*min. Note if RRT 0.69 peak area was >0.04µS*min, column was washed with 2 CV of purified water and IPC was repeat.
12. If column was to be stored for less than 1 week; column was flushed with 2 CV of either water or 1 M HCl every 24 hours alternating daily.
13. If column was to be stored for >1 week the column was flushed with 2 CV 20% NaCl every 7 days. After storage in NaCl the column was flushed with 5 CV of water and the activation procedure (steps 7-9) was carried out x4 prior a final activation (steps 7-10) prior to use.
14. If the activated column is not used within 4h, steps 7-10 were repeated.
15. 3.36 L (4.8 volumes) of purified water were charged to a reactor with jacket temp 24 ±3° C. Stirring started at medium-high speed and 0.7 Kg dodecasodium phytate were added slowly over 30 minutes. The reaction was lightly exothermic, requiring control of the speed of addition to keep temperature below 30° C. Mixture was stirred for further 60 minutes, ensuring full dissolution was achieved.
16. The solution was transferred with filtration from the reactor into drum(s).
17. 1 CV of purified water was flowed through the column. Flowing of phytate solution from step 15 immediately commence through vessel with pump at same setting used in step 7-10. Note: Actual flow rate during sample addition was slightly reduced due to increased viscosity.
18. Fraction collection commenced once loading of sample started and pH was measured throughout elution and subsequent wash. Fraction size was approximately ⅛ of the CV (approximately 10 L) but new containers were taken at specific pH as stated even if current fraction was not full.
19. Container was changed once pH <1.5, again pH <1.25, and when pH <1.0.
20. The solution was chased with 1 CV purified water and fraction collection restarted in new container until pH >1.0, changed again when pH > 1.25, and again when pH > 1.5.
21. pH probe was rinsed in purified water and pH of fractions was retaken. Samples of the appropriate fractions (pH >2) from each container were submitted for UV testing.
22. Steps 7-10 were repeated to reactivate resin.
23. The appropriate fractions were combined into the reactor with jacket temperature 24 ± 3° C. Stirring was started at medium-high speed. 0.7 Kg dodecasodium phytate were added slowly over 30 min. The reaction was slightly exothermic. Speed of addition was controlled to keep temperature below 30° C. Stirring continue for further 60 minutes, ensuring full dissolution was achieved.
24. Solutions were transferred with filtration from reactor to drum(s).
25. Steps 17-21 were repeated for exchange and collection of pass 2.
26. Steps 14-25 were repeated until the entire batch has been processed.
27. Steps 14-21 were repeated for exchange and collection if a third pass is required, which depended on the amount of starting material to be processed.
28. Appropriate fractions were combined. Weight was measured and a sample was taken for IPC2. IPC2: IC phytic acid content mg/ml, report result.
29. Three volumes of ethanol with respect to expected total phytic acid weight were loaded to the reactor and chilled to 5° C.
30. Based on IPC2 and volume of exchanged solution, an appropriate volume was charged to a reactor whose distillation rate would allow removal of target volume in <8 hours. Distillation took place at temperature 40° C. Maximum temperature did not exceed 45° C. until target distillate volume had been removed or maximum distillation time of 8 hours was reached. A sample was submitted for IPC3. IPC3: water content by KF, ≤45% w/w and IPC4: IC purity and assay, report result. Temperature was reduced to 0-5° C. while waiting on results. Note: Syrup should be colorless to very pale yellow.
31. If IPC3 passed, the process proceeded to step 32. If IPC3 failed, process was stopped. IC purity was used to determine how to proceed.
32. If required purified water was added to give 45% w/w, calculated by using IPC2 result and distillate weight. 3 volumes of ethanol with respect to total weight phytic acid in the portion were added at 20° C. until fully mixed. The mixture was discharge with filtration into the appropriate reactor with jacket at 5° C. The reactor was rinsed with 2 volumes of ethanol with respect to the phytic acid in the respective distillation portion and transferred with filtration into reactor containing chilled ethanol from step 29.
33. Prior to charging next portion, reactor was rinsed with 20 L of purified water. Rinse was kept as hold pool. 2 further washes with purified water were discarded.
34. Steps 30 and 33 were repeated until all product solution from step 28 had been processed.
35. Total weight of phytic acid added to the reactor and total volume ethanol used to discharge syrup were calculated. Ethanol was added. The amount of ethanol should be 2 volumes, so a total of 10 volumes were charged to the reactor.
36. Reactor jacket temperature was set to 15° C. The solution was stirred until internal temperature reached 15° C.
37. Jacket temperature was reset to 10° C. Solution was stirred at 130 RPM. Sodium methoxide was added portion wise at a rate of 2.5% per minute, e.g., a 25% charge should take 10 minutes to add. Charge was calculated from IPC2.
pH was monitored throughout addition of portion. Addition was stopped if pH >5.0 at any point. Mixture was allowed to equilibrate, and pH retaken after 5 minutes. After addition of 85% of the total charge, equilibration time was set to 15 minutes. Sodium methoxide continued to be added in smaller portions until within pH 4.3-5.3 range. At that point addition of sodium methoxide (~97% of calculated amount of sodium methoxide) was terminated, and volume charged was recorded, and the process continued to step 38. If pH was below this range, sodium methoxide continued to be added in 1% portions with continued monitoring of pH until pH within range, target pH 4.8. The amount of sodium methoxide may be less that the amount calculated but should not be exceeded. Note: if temperature increased above 20° C., addition of sodium methoxide was paused until temperature decreased to 15 ± 2° C.
38. Slurry was chilled to 5° C. with a jacket temperature of 0° C. Once internal temperature reached 5° C. jacket temperature was raised to 5° C. Stirring proceeded for 30 minutes. A sample was taken for IPC5. IPC5: test pH range 4.3-5.3 (target 4.8). If IPC5 passed, the process proceeded to step 39. If IPC5 failed, 1% portions of sodium methoxide were added, equilibrated for 30 minutes, and pH tested until pH remained within the pH 4.3-5.3 range. Addition stopped immediately if pH >4.8, in which case it was allowed to equilibrate, and pH retaken after 15 minutes. If pH within pH 4.3-5.3 range, addition of sodium methoxide was terminated, volume charged was recorded, and the process continued to step 39.
39. Slurry was stirred at 5° C. for further 1.5 hours, then internal temperature was increased to 10° C., with maximum jacket temperature at 15° C. 10 volumes of acetone were added. The mixture was stirred for 60 minutes and then the jacket temperature was decreased to 0° C. Stirring continued until internal temperature reached 5° C. At that point jacket temperature was raised to 5° C. and the mixture stirred for 30 minutes.
40. Solid was isolated using centrifuge under nitrogen until a dry solid was obtained. This was done portion wise with the cake being removed after each portion of solution was processed. Each cake was washed with 2 volumes of acetone with respect to the phytic acid weight from IPC2 prior to discharge.
41. Reactor was charged with 10 volumes of acetone. All portions of cake from step 40 were recharged. The slurry was stirred at 15° C. for 1.5 hours.
42. Jacket temperature was set to 0° C. and solution was chilled to 5° C. Once slurry reached 5° C. jacket temperature was raised to 5° C. and slurry was stirred for 30 minutes.
43. Solid was isolated using centrifuge under nitrogen until a dry solid was obtained. This was done portion wise with the cake being removed after half the solution if processed. Each cake was washed with 2 volumes of acetone with respect to phytic acid weight from IPC2 prior to discharge.
44. Reactor was charged with 10 volumes of acetone. All portions of cake from step 43 were recharged. Slurry was stirred at 15° C. for 1.5 hours.
45. Jacket temperature was set to 0° C. Solution was chilled to 5° C. Once slurry reached 5° C. jacket temperature was raised to 5° C. Slurry was stirred for 30 minutes.
46. Solid was isolated using centrifuge under nitrogen until a dry solid was obtained. Each cake was washed with 2 volumes of acetone with respect to the phytic acid weight from IPC2 prior to discharge.
47. All material from step 46 was charged to a vacuum oven and dried without heat and with small nitrogen bleed. Cake was broken/stirred up every 6 hours. After 24 hours a sample was taken for IPC6. IPC6: KF Stromboli <8% w/w. Drying continued until IPC6 result returned or maximum 48 hour drying time reached. If IPC6 passed, the process proceeded to step 48, if IPC6 failed, drying continued until 48 hours total time was reached and another sample was taken for IPC6. Trays were discharged from the oven and stored at -20° C. under desiccant whilst awaiting IPC6 results. If IPC6 2nd sample passed, the process proceeded to step 49. IPC6 2nd sample should be submitted for IPC7: IC purity report result w/w on an anhydrous basis. If IPC6 2nd sample failed, the process proceeded to step 48. Note: The sample to be analyzed was the same sample that was analyzed as IPC6 as water content was required for reporting result.
48. It was decided whether further drying was feasible or necessary.
49. The same sample that passed IPC6 was used for IPC8 and IPC9 as IPC9 was expressed on an anhydrous and solvent free basis.
50. IPC8: residual solvent by GC, ethanol <20000 ppm, methanol <5000 ppm, acetone <5000 ppm. Material was held at -20° C. under desiccant while waiting on IPC8 result. If IPC8 failed, the process was stopped. If IPC8 passed, the process proceeded to step 51. Note: The sample to be analyzed in IPC8 was the final sample that was analyzed as IPC6.
51. IPC9: Sodium content by ICP-MS, 15.4-19.5 on an anhydrous and solvent free basis. Material was held at -20° C. under desiccant while waiting on result. If IPC9 filed, process stopped. If IPC9 passed, process proceeded to step 52. Note: The sample to be analyzed as IPC9 was the final sample that was analyzed as IPC6 and IPC7.
52. Solid was discharged into liners, doubled with desiccant sachets between liners and in curtec drum.
During the crystallization, all equivalents and volumes were relative to crude hexasodium phytate input.
As a result of this process, Na6IP6 salt 73.4% w/w pure containing the following impurities was obtained:
A comparison of the products obtained in Processes 1, 2, and 3 is presented in Table 9, See below.
The manufacture of Na6IP6 from recrystallized Na12IP6 comprised the following steps in Process 3. This process was developed to improve the drug substance quality by significantly reducing its impurities content. The process introduces an additional purification step of the starting material, i.e., phytic acid dodecasodium salt hydrate, by recrystallization from a water solution. Further steps conducted with the purified phytic acid dodecasodium salt isolated intermediate up to the isolation of the purified drug substance consists essentially of the same three-step ion-salt exchanges previously described for Process 2. The flow-chart for SNF472 (hexasodium phytate) Process 3 is shown in
(A) Recrystallized starting material: Dodecasodium salt was recrystallized as described in Examples 2 and 3.
(B) Hexasodium phytate preparation:
1. A column was flushed with 3 CV (column volumes) of purified water and emptied.
Approximately 0.25 CV of purified water were added to the column.
2. Resin equivalent to ~75% of CV was added, and purified water was added required to keep the level of water just above the surface of the resin.
3. Resin and water were added until the column was sufficiently packed. The top of the column was screwed and attached to a diaphragm pump (in reverse).
4. At least 5 CV of purified water were flowed through the resin in reverse flow (bottom to top). Lines were switched so flow was top to bottom and at least 5 CV were flowed through.
5. 5 CV 1 M HCl were flowed through the column. If pH at end volume <0.4, process continued to step 7, if pH >0.4 it continued to step 6.
6. 1 CV 1 M HCl was flowed through the column at 3250 mL/min ± 100 mL/min, if pH at end volume <0.4 the process continued to step 7, if >0.4 step 6 was repeated until <0.4.
7. 4 CV of purified water were flowed through column. If pH at end volume >3.25 process continue to step 9. If pH <3.25 process continued to step 8.
8. 1 CV of purified water was flowed through column. If pH at end volume >3.25 proceed continued to step 9.
9. Sample that passed pH check in steps ⅞ was used as IPC1. IPC1: Purity by IC of final purified water wash. Target: RRT 0.69 area ≤ 0.04µS∗min. Note if RRT 0.69 peak area is >0.04µS*min column was washed with 2 CV of purified water and IPC was repeated.
10. Column was activated by repeating steps 5-8.
11. Reactor was charged with 4.8 volumes purified water (with respect to dodecasodium phytate volume). Reactor jacket temperature was set at 24° C. ±3° C. Stirring was started at medium-high speed and 0.7 kg dodecasodium phytate were added slowly over 30 minutes. The reaction was slightly exothermic; therefore, speed of addition was controlled to keep temperature below 30° C. (target temperature was 24° C.). Stirring continued for further 60 minutes, ensuring that full dissolution was achieved.
12. Solution was kept under agitation at between 20-25° C. until column had been confirmed as activated and fit to use. Only then the solution was transferred, with filtration, from reactor into drum(s).
13. 1 CV purified water was flowed through the column. Flowing of the phytate solution from step 12 was initiated immediately through the column with pump at same setting used during activation.
14. Fraction collection commenced once loading of sample started and pH was measured throughout elution and subsequent wash. Fraction size was approximately ⅛ of the CV but new containers were taken at specific pHs as stated even if the current fraction was not full.
15. Containers were changed once pH <1.5, again when pH <1.25 and again when pH <1.0.
16. The solution was chased immediately with 1 CV purified water and fraction collection restarted in new container until pH >1.0, changed again when pH > 1.25 and again when pH >1.5.
17. pH probe was rinsed well in purified water and pH of fractions was retaken. Samples from appropriate fractions (pH <2) from each container were submitted for UV testing. Fractions were stored at 2-8° C. until further processing.
18. The resin reactivation steps were repeated.
19. The appropriate fractions for Pass 1 were combined:
pH <1.00: all fractions with pH less than one should be combined.
1.00 < pH < 1.25: most fractions likely to be combined unless UV analysis indicates very weak concentration.
1.25 < pH < 1.50 unlikely to be included unless UV indicates a significant amount of product present.
20. The combined fractions from the previous step were transferred into the reactor with jacket temperature at 24° C. ±3° C. and stirring at medium-high speed was started. Additional dodecasodium phytate was added slowly over 30 min. The reaction was slightly exothermic, so speed of addition was controlled to keep the temperature below 30° C. The solution was stirred for further 60 minutes, ensuring full dissolution was achieved.
21. Solution was maintained under agitation between 20-25° C. until the column had been confirmed as activated and fit to use. Only then the solution was transferred, with filtration, from the reactor into drum(s).
22. Steps 13-17 were repeated for ionic exchange and collection of pass 2.
23. The appropriate fractions for Pass 2 were combined according to the criteria below:
pH <1.00: all fraction pH less than one should be combined.
1.00 < pH < 1.25: may not be combined unless UV analysis indicated a significant amount of product present.
1.25 < pH < 1.50 should not be included for Pass 2 unless project chemist indicated otherwise.
24. Steps 10 through 23 were repeated until the entire batch was processed.
25. Appropriate Pass 2 fractions from all runs were combined, weight was measured, and a sample was taken for IPC2. IPC2: IC phytic acid content mg/mL. Determine density.
26. 2 volumes of ethanol with respect to expected total phytic acid weight determined from IPC2, solution weight and density, were loaded to reactor and chilled to 5° C.
27. Based on IPC2 appropriate volume was charged to a reactor whose distillation rate would allow removal of target volume in <10 h, maximum 12 h. The amount of water to be removed was calculated using IPC2 value, and volume to be charged based on an expected final syrup water content of 40%.
28. The solution was distilled with aim to keep internal temperature <40° C. Internal temperature must not exceed 45° C., no lower limit. Syrup should be colorless to very pale yellow.
29. Distillation rate was corrected over the first 2 hours if it was not sufficient to remove required amount of water within maximum allowed time.
30. Once target distillate volume had been removed, a sample was taken for IPC3. IPC3A: water content by KF, ≤45% w/w. IPC3B: IC purity and assay, report result. If IPC3A passed, the process proceeded to step 32. If IPC3A failed, distillation process continued as appropriate up to the maximum distillation time of 12 hours, and additional times was used if needed.
31. If maximum distillation time of 12 h was reached before IPC3A passed, a sample for IPC3 was submitted at this time point and the batch was cooled to 5-8° C. If IPC3A passed, the process proceeded to step 32.
32. If required, purified water was added to give 45% w/w. Value was calculated by using IPC2 result, density and weight solution charged, then 3 volumes of ethanol with respect to total weight phytic acid were added in the portion and agitated at 20° C. until fully mixed. The solution was discharged with filtration into the appropriate reactor with jacket at 5° C. The reactor was rinsed with 3 volumes of ethanol with respect to the phytic acid in the respective distillation portion and transferred with filtration into reactor containing chilled ethanol.
33. Prior to charging next portion, reactor was rinsed with 3 volumes (or appropriate volume for reactor size) of purified water and keep rinse as hold pool. Further washes were discarded.
34. Steps 27 and 31 were repeated until all product solution from step 21 had been processed.
35. Total weight of phytic acid added to the reactor was calculated and also the total volume of ethanol used to discharge syrup. Ethanol was added. The amount of ethanol was 10 volumes with respect to the total amount of phytic acid that had been charged to the reactor.
36. Reactor jacket was set to 15° C. and the solution was stirred until internal temperature reached 15° C.
37. Jacket temperature was reset to 10° C., solution was stirred at 130 RPM, and the sodium methoxide was added portion wise at a rate of 2.5% per minute, e.g., a 25% charge should take 10 minutes to add. Charge calculated from IPC2.
pH was monitored throughout the addition of portions. Addition was stopped if pH >5.0 at any point.
The amount of sodium methoxide may be less that the amount calculated but should not exceed 105% of theoretical calculated using IPC2.
38. Slurry was chilled to 5° C. with a jacket temperature of 0° C. Once internal temperature reached 5° C. jacket temperature was raised to 5° C. Slurry was stirred for 30 minutes, and a sample representative of the slurry mix taken for IPC4. IPC4: test pH range 4.3-5.3 (target 4.8). If IPC4 passed, the process proceeded to step 39. If it failed, 1% portions of sodium methoxide were added, equilibrated 30 minutes, and pH was tested until it remained within range 4.3-5.3. Addition was immediately stopped if pH >4.8. If pH was within pH range of 4.3-5.3, addition of sodium methoxide was terminated, volume charged was recorded, and a sample was taken for IPC4. IPC4: test pH range 4.3-5.3 (target 4.8). If samples passed, process proceeded to step 39. If it failed, then the failure loop was repeated.
39. Slurry was stirred at 5° C. for further 1.5 hours, and then internal temperature was increased to 10° C. Maximum jacket temperature was 15° C. 10 volumes of acetone were added. The mixture was stirred for 60 minutes, jacket temperature was decreased to 0° C., and stirring continued until internal temperature reached 5° C. Jacket temperature was raised to 5° C. and mixture stirred for 30 minutes.
40. The solid was isolated using filtration under nitrogen (solid is hygroscopic). Reactor was rinsed with 2 × 3 volumes of acetone with respect to phytic acid weight from IPC2. Rinse was used to wash cake prior to discharge.
41. Reactor was charged with 25 volumes of acetone. All wet cake from step 38 was recharged. The slurry was stirred at 15° C. for 1.5 hours.
42. Jacket temperature was set to 0° C., and the solution was chilled to 5° C. Once slurry reached 5° C., jacket temperature was raised to 5° C. and solution was stirred for 30 minutes.
43. Solid was isolated using filtration under nitrogen (solid is hygroscopic). Reactor was rinsed with 2 × 3 volumes of acetone with respect to phytic acid weight from IPC2. Rinse was used to wash cake prior to discharge.
44. Reactor was charged with 25 volumes of acetone. All wet cake from step 41 was recharged into the reactor, and the slurry was stirred at 15° C. for 1.5 hours.
45. Jacket temperature was set to 0° C., and slurry was chilled to 5° C. Once slurry reached 5° C. jacket temperature was raised to 5° C. and the slurry was stirred for 30 minutes.
46. Solid was isolated using filtration under nitrogen (solid is hygroscopic). Reactor was rinsed reactor with 2 × 3 volumes of acetone with respect to phytic acid weight from IPC2. Rinse was used to wash cake prior to discharge.
47. Cake was deposited on filter under nitrogen without heat. Cake was broken up/stirred every 6 hours. After 24 hours a sample was taken for IPC5A: KF Stromboli <8% w/w. Cake continue drying until IPC5A result returned or maximum 48 hours drying time reached. If IPC5A failed, drying continued, taking samples for IPC5A until 48 h total time was reached. If IPC5A passes, IPC5B was carried out: IPC5B: residual solvent by GC, ethanol <20000 ppm, methanol <5000 ppm, acetone <5000 ppm. The drying of the product on the filter continued whilst awaiting results unless max drying time was reached. When both IPC5A and IPC5B passed the process proceeded to step 50. If IPC5A or IPC5B did not pass and maximum drying time was reached, the process continued to step 48.
48. If max drying time was reached and results IPC5A/IPC5B had not been returned or failed, product was discharged from filter and store in double liners at -20° C. under desiccant whilst awaiting results. If both IPC5A and IPC5B passed, the process proceeded to step 50; if not it proceeded to step 49.
49. Assess whether further drying is necessary/advisable.
50. Discharge into liners, doubled with desiccant sachets between liners and in curtec drum.
Solvents used in the process were purified water (USP pharmaceutical), acetone (99%), sodium methoxide (25% w/w in methanol) and ethanol (99.4%).
As a result of this process, Na6IP6 salt 82.1% w/w pure containing the following impurities was obtained:
A comparison of the product obtained in Processes 1, 2, and 3 is presented in Table 9, See below.
31P- NMR
1H- NMR
The hexapotassium salt of IP6 (K6IP6) is prepared using the process disclosed in Example 7 but using K12IP6 prepared according to the process described in Example 4 or Na12IP6 prepared according to the process described in Examples 2 or 3. The method also uses a potassium alkoxide, e.g., potassium methoxide, as a replacement for the sodium alkoxide used in Example 7.
The manufacture of Na6IP6 from recrystallized Na12IP6 using an ion exchange batch process comprised the following steps:
1. Charge 5.72 eq of an ion exchange AMBERLITE® FPCC14 Na resin (Rohm and Haas Co., Philadelphia, PA, US) to a clean, dry filter and wash with 1 M hydrochloric acid (3.7 vols).
2. IPC 1: pH check by pH paper. Target: pH 1-2. Note: If pH >2 then wash the resin with 1 M hydrochloric acid (3.7 vols).
3. Wash resin with 1 M hydrochloric acid (3 × 3.7 vols).
4. Wash resin with purified water (7 × 3.7 vols).
5. IPC 2: pH check by pH meter of final purified water wash. Target: pH >3.5. Note: If pH <3.5 then wash the resin with purified water (2 × 3.7 vols).
6. IPC 3: Purity by IC of final purified water wash. Target: RRT 0.69 peak area <0.04 µS*min. Note: If RRT 0.69 peak area is >0.04 µS*min wash the resin with purified water (2 × 3.7 vols).
7. Store the resin in double liner into a drum until next use.
8. Charge purified water (7.0 vols) to a clean, dry mobile reactor at 25° C.
9. Charge phytic acid dodecasodium salt (1.0 eq) slowly to the mobile reactor at 27 ± 3° C. maintaining the temperature below 35° C. and stir for 1 ± 0.5 hour until dissolution occurs. Note: Solution is pH 11/12. Exotherm of 5° C. is typically observed. If dissolution does not occur, increase temperature to 30 ± 3° C. to help aid dissolution.
10. Charge phytic acid dodecasodium salt solution in water via a polishing filter to a clean, dry reactor at 27 ± 3° C.
11. Check that no particulates are present.
12. Charge the washed resin (5.72 eq) to the reaction mixture at 27 ± 3° C. with gentle stirring (~100 rpm).
13. Adjust the temperature to 23 ± 2° C. and stir the solution gently (~100 rpm) for a minimum of 12 hours. Note: Stirring at >100 rpm breaks up resin to a fine powder.
14. IPC 4: pH check by pH paper. Target: pH 1-2. Note: If reaction mixture is >pH 2 increase agitation slightly to ensure sufficient agitation of the resin throughout the solution and take further IPC 4 samples every 1-2 hours until a pH of 1-2 is reached.
15. Filter off the resin and wash with purified water (2 × 2.5 vols) keeping the washes separate.
16. IPC 5: pH check by pH meter of wash. Target: pH >1.85. Note: If pH <1.85 wash the resin with purified water (2.5 vols).
17. Charge a fresh portion of the ion exchange resin (2.0 eq) to a clean, dry filter and wash with 1 M hydrochloric acid (1.3 vols).
18. IPC 6: pH check by pH paper. Target: pH 1-2. Note: If pH >2 then wash the resin with 1 M hydrochloric acid (1.3 vols).
19. Wash the resin with 1 M hydrochloric acid (3 × 1.3 vols).
20. Wash the resin with purified water (7 × 1.3 vols).
21. IPC 7: pH check by pH meter of final purified water wash. Target: pH >3.5. Note: If pH <3.5 then wash the resin with purified water (2 × 1.3 vols).
22. IPC 8: Purity by IC of final purified water wash. Target: RRT 0.69 peak area <0.04 µS*min. Note: If RRT 0.69 peak area is >0.04 µS*min wash the resin with purified water (2 × 1.3 vols).
23. Elute the colorless filtrate through the washed resin collecting in ~5 L fractions.
24. Elute the washes followed by purified water through the resin in ~2.5 L portions and collect the fractions. Note: Elute purified water through the resin until IPC 9 pH rises to >1.85. Typically, ~1.5 vols water is eluted through the resin.
25. IPC 9: pH check by pH meter. Target: pH of last fraction >1.85. Check pH of the fractions and combine those with a pH of <1.85.
Store phytic acid solution at <10° C.
The hexasodium salt of IP6 (Na6IP6) is prepared using the process disclosed in Example 7 (Process 3) but using sodium ethoxide (CH3CH2NaO) as a replacement for sodium methoxide alkoxide (CH3NaO).
Step 1 - Aqueous solution: A 14% (w/v) Na6IP6 solution was prepared by dissolving Na6IP6 obtained according to the protocol described in Example 7 (Process 3) in water. The solution was divided in three 20 mL batches and one large 100 mL batch.
Step 2 - Spray drying: All batches were spray dried using a Büchi B-290 spray dryer (Büchi Labortechnik AG, Flawil, CH) fitted with a Büchi two-fluid spray nozzle. The spray dryer was fitted with a high-performance cyclone for the three 20 mL batches and a standard cyclone for the 100 mL batch. The spray drying conditions used were 3 g/min (liquid fed rate), 2 bar (atomization pressure), 68-122° C. (inlet temp), 50-90° C. (outlet temp). Outlet temperatures of 50, 70 and 90° C. were used for the three 20 mL batches. An outlet temperature of 90° C. was selected for the 100 mL. All four batches were spray dried successfully with yields ranging from 89.3% to 95.8%. See Table 10.
The manufacture of Na6IP6 using non-recrystallized Na12IP6 instead of recrystallized Na12IP6 as starting material was assayed according to the protocol described in Example 7 (Process 3):
(A) Starting material: Unpurified phytic acid dodecasodium salt (Sigma-Aldrich, Saint Louis, MO, US) was employed as starting material.
(B) Unpurified hexasodium phytate preparation: Unpurified hexasodium phytate was prepared using the Phase A starting material and following steps 1-49 of Example 7 (Process 3).
(C) Purified hexasodium phytate preparation: Purified hexasodium phytate was prepared by recrystallizing the Phase B intermediate product according to the protocols described in either Examples 2 or 3.
The manufacture of Na6IP6 using non-recrystallized K12IP6 as starting material was assayed according to the protocol described in Example 7 (Process 3):
(A) Starting material: Unpurified phytic acid dodecapotassium salt was employed as starting material.
(B) Unpurified hexasodium phytate preparation: Unpurified hexasodium phytate was prepared using the Phase A starting material and following steps 1-49 of Example 7 (Process 3).
(C) Purified hexasodium phytate preparation: Purified hexasodium phytate was prepared by recrystallizing the Phase B intermediate product according to the protocols described in either Examples 2 or 3.
The manufacture of Na5IP6 using non-recrystallized Na10IP6 as starting material was assayed according to the protocol described in Example 7 (Process 3).
(A) Starting material: Unpurified phytic acid decasodium salt (Sigma-Aldrich, Saint Louis, MO, US) was employed as starting material.
(B) Unpurified pentasodium phytate preparation: Unpurified pentasodium phytate was prepared using the Phase A starting material and following steps 1-49 of Example 7 (Process 3).
(C) Purified pentasodium phytate preparation: Purified pentasodium phytate was prepared by recrystallizing the Phase B intermediate product according to the protocols described in either Examples 2 or 3.
The Na6IP6 drug substance was fully characterized by a combination of spectroscopic techniques (mono and bidimensional nuclear magnetic resonance 1H-NMR, 31P-NMR,13C-NMR ultraviolet-visible spectroscopy, infrared spectroscopy, and mass spectrometry), elemental analysis and chromatographic techniques (ion-exchange chromatography (IC)).
Nuclear magnetic resonance: The structure was confirmed by the nuclear magnetic resonance studies, according to the assignment of the signals shown in Table 11, and the identification was further confirmed by ion-exchange chromatography, according to the phytic acid reference standard retention time. Table 11 lists the chemical shifts, multiplicities and coupling constants obtained from a multi- nuclear and multidimensional study of Na6IP6 (hexasodium phytate). These data unequivocally established the structure of this molecule as that of structure proposed in hexasodium phytate shown in
31P-NMR, 1H-NMR and 13C-NMR Chemical Shift Data for Na6IP6 (hexasodium phytate)
3J-(1H-1H) Coupling Constants c
a Taken from
b Taken from
c Taken from
d Taken from
There were only four peaks in the 31P-NMR spectrum, with an integral ratio of 1:2:2:1 (
Assignments of protons are shown in Table 11. The easiest proton to assign in
The DEPT 135 spectrum of Na6IP6 is shown in
Ultraviolet-Visible spectroscopy: Na6IP6 is a compound which has no characteristic absorption spectra in ultraviolet or visible region typical in the group of inositol phosphates.
FT-Infrared spectroscopy: The FT-IR spectrum of Na6IP6 is shown in
Mass spectrometry: The molecular mass of Na6IP6 was confirmed by the peak corresponding to the molecular ion of m/z 659 ([M-H]-) by tandem mass spectrometry in the selected ion monitoring (SIM) mode after negative electrospray ionization (ESI). The molecular ion of m/z 659 ([M-H]-) corresponded to phytic acid molecule (m/z = 660) that had lost a hydrogen atom during negative electrospray ionization. The compound was analyzed by gradient reversed-phase chromatography using TEAA 50 mM pH 9 and ACN as mobile phase injecting 20 µL into the UPLC®-MS. The mass spectrum of
Elemental analysis, Sodium content (%Na) and Phosphorus content (%P): Elemental analysis of Na6IP6 was carried out and the results are included in Table 12. Characterizing the contribution of cations to the elemental composition of Na6IP6 (hexasodium salt) the Sodium content (%) in conjunction with total Phosphorous content (%) allowed to assess the stoichiometric ratio of the salt, which at the same time was an indication of purity. Sodium content found was close to the calculated theoretical value thus confirming that the stoichiometry of Na6IP6 conformed to the hexasodium salt (6 mol sodium per mol phytic acid).
a Minor variation in calculated and found values is attributed to the content of water in the sample.
b Phosphorus and sodium content measured by ICP-OES.
Ion exchange chromatography: The spectroscopic data was further confirmed by ion-exchange chromatography in which the retention time of the phytic acid peak in Na6IP6 was compared to that of the phytic acid peak in an analytical reference standard under the same chromatographic conditions. See
Polymorphism: Na6IP6 was isolated as an amorphous solid material. Several attempts to isolate Na6IP6 as a crystalline material were performed but did not reveal any evidence of a polymorph.
In conclusion, the structural elucidation studies carried out on Na6IP6 together with the synthetic route used for its preparation are consistent with and fully support the proposed structure.
Step 1 - Compounding (preparation of solution): Components (e.g., Na6IP6 obtained from recrystallized Na12IP6 or non-recrystallized Na12IP6) were diluted with water for injection in a dedicated 400L mixing bag equipped with a magnetic stirrer. The batch composition was detailed in the table below. The pH was adjusted to 6.0 ± 0.4 with a 6.0 M NaOH solution.
∗6.0 M NaOH solution (allows a faster adjustment with a minimum impact on drug product volume)
Step 2 -Filtration: The final bulk solution was filtered through a single-use filtration transfer equipped with a 0.2 µm PES filter.
Step 3 -Solution collection: The filtered solution was collected into a 400 L feeder bag.
Step 4 - Filling process: A filling machine feeder bag was used. The filtered final bulk was filled into glass vials type I.
Step 5 - Stoppering and capping: Vials were stoppered, and caps were placed on the stoppered vials with a capping machine.
Step 6 - Visual inspection and testing: 100 % of the vials were visually inspected and the drug product was analyzed according to the established specifications
Step 7 - Storage: Vials were bulk packed into secondary packaging and transferred to warehouse for storage at 2-8° C. until shipment.
A Na6IP6 aqueous pharmaceutical composition having the ingredients and content according to the protocol described in Example 16 (i.e., Table 13) was prepared. The recrystallized Na6IP6 salt used for preparing the solution was obtained and characterized according to the protocol described in Example 7.
Aliquots of the Na6IP6 aqueous pharmaceutical composition were stored at: (i) -20° C., and (ii) 5° C. for 12 months, and (iii) at 25° C. and 60% relative humidity (RH) for 6 months. The stability of the items (i) and (ii) aliquots was assayed at the beginning and at 3, 6, 9, and 12 months. The stability of the item (iii) aliquots was assayed at the beginning and at 1, 3, and 6 months. The ion chromatography protocols described above were used for assessing stability. All the Na6IP6 aqueous pharmaceutical compositions were found to be stable and within specifications at all temperatures and RH conditions tried. See Tables 14 and 15. These results show that the Na6IP6 aqueous pharmaceutical compositions are stable at room temperature.
It is to be appreciated that the Detailed Description section, and not the Summary and Abstract sections, is intended to be used to interpret the claims. The Summary and Abstract sections may set forth one or more but not all exemplary embodiments of the present invention as contemplated by the inventor(s), and thus, are not intended to limit the present invention and the appended claims in any way.
The present invention has been described above with the aid of functional building blocks illustrating the implementation of specified functions and relationships thereof. The boundaries of these functional building blocks have been arbitrarily defined herein for the convenience of the description. Alternate boundaries can be defined so long as the specified functions and relationships thereof are appropriately performed.
The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying knowledge within the skill of the art, readily modify and/or adapt for various applications such specific embodiments, without undue experimentation, without departing from the general concept of the present invention. Therefore, such adaptations and modifications are intended to be within the meaning and range of equivalents of the disclosed embodiments, based on the teaching and guidance presented herein. It is to be understood that the phraseology or terminology herein is for the purpose of description and not of limitation, such that the terminology or phraseology of the present specification is to be interpreted by the person skilled in the art in light of the teachings and guidance. All the cited references are incorporated to the description in their entireties.
The breadth and scope of the present invention should not be limited to any of the above-described examples or aspects but should be defined only in accordance with the following claims and its equivalents.
| Number | Date | Country | Kind |
|---|---|---|---|
| 20383092.2 | Dec 2020 | EP | regional |
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/EP2021/085854 | Dec 2021 | WO |
| Child | 18320823 | US |
